Targeting receptor tyrosine kinase signaling in acute myeloid leukemia by Doepfner, K T
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Targeting receptor tyrosine kinase signaling in acute myeloid
leukemia
Doepfner, K T
Doepfner, K T. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. 2008, University of Zurich,
Faculty of Science.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Science, 2008.
Doepfner, K T. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. 2008, University of Zurich,
Faculty of Science.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
University of Zurich, Faculty of Science, 2008.
 
 
 
Targeting Receptor Tyrosine Kinase Signaling in Acute Myeloid Leukemia 
 
  
 
 
Dissertation 
zur  
Erlangung der naturwissenschaftlichen Doktorwürde  
(Dr. sc. nat.)  
vorgelegt der  
Mathematisch-naturwissenschaftlichen Fakultät  
der  
Universität Zürich  
 
 
von  
Kathrin T. Doepfner 
aus Zürich 
 
 
Promotionskomitee 
Prof. Dr. Josef Jiricny (Vorsitz)     
Prof. Dr. Ernst Hafen 
Dr. Alexandre Arcaro (Leitung der Dissertation) 
 
 
 
Zürich, 2007  
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diese Arbeit wurde in der Gruppe von Dr. Alexandre Arcaro in der Abteilung für Klinische 
Chemie und Biochemie (Leiter: Prof. Dr. C. W. Heizmann) und in der Abteilung für Onkologie 
(Leiter: Prof. Dr. F. K. Niggli) des Universitäts Kinderspital Zürich durchgeführt. 
 
PhD Thesis  Table of Contents 
III 
 
TABLE OF CONTENTS 
 
 
1. A.  SUMMARY............................................................................................................................. 1 
 B.  ZUSAMMENFASSUNG......................................................................................................... 3 
 
2. INTRODUCTION ........................................................................................................................ 6 
 2.1. Acute Myeloid Leukemia ...................................................................................................... 6 
  2.1.1.   Pathogenesis ............................................................................................................. 8 
  2.1.2.   Genetic Alterations Involving Transcription Factors .................................................. 9 
 2.2. Receptor Tyrosine Kinase Signaling.................................................................................... 10 
  2.2.1.   Insulin-like Growth Factor I Receptor Signaling ...................................................... 13 
   2.2.1.1.   The Role of the IGF-IR in Human Cancer ...................................................... 14 
  2.2.2.   Phosphoinositide 3-Kinases ..................................................................................... 17 
   2.2.2.1.   Inhibition of PI3K Signaling .......................................................................... 19 
   2.2.2.2.   Gene-Targeting Strategies .............................................................................. 19 
   2.2.2.3.   PI3K and Diseases ......................................................................................... 22 
  2.2.3.   Alteration of RTK Signaling in AML ...................................................................... 24 
  2.2.4.   Targeting RTK Signaling in AML ........................................................................... 26 
   2.2.4.1.   FLT3.............................................................................................................. 27 
   2.2.4.2.   c-Kit .............................................................................................................. 29 
   2.2.4.3.   IGF-IR ........................................................................................................... 30 
  2.2.5.   Downstream Signal Transducers.............................................................................. 31 
   2.2.5.1.   PI3K/AKT...................................................................................................... 32 
   2.2.5.2.   mTOR ............................................................................................................ 33 
   2.2.5.3.   RAS/RAF/MEK/ERK..................................................................................... 33 
 
3. RESULTS ................................................................................................................................... 36 
 3.1. Aims ................................................................................................................................... 36 
 3.2. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human  
acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway ........................ 39 
 3.3. Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain tumours  
and neuroendocrine tumours ................................................................................................ 51 
 3.4. Investigation of the molecular determinants of rapamycin sensitivity in acute myeloid  
leukemia cells...................................................................................................................... 81 
PhD Thesis  Table of Contents 
 
IV 
 
 
 3.5. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells ............105 
 3.6. Targeting the phosphoinositide 3-????????????????????????????????????????????????? 
in neuroblastoma cells.........................................................................................................115 
 
4. CONCLUSIONS AND PERSPECTIVES .................................................................................143 
 
5. REFERENCES ..........................................................................................................................147 
 
6. CURRICULUM VITAE ............................................................................................................161 
 
7. ACKNOWLEDGEMENTS .......................................................................................................166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PhD Thesis  Abbreviations 
V 
ABBREVIATIONS 
 
AML Acute Myeloid Leukemia 
Ara-C Cytarabine 
ATRA All-Trans-Retinoic Acid 
AT/RT Atypical Teratoid/Rhabdoid Tumor 
CBF Core Binding Factor 
CBF-AML  Core Binding Factor Leukemia 
CBP  Creb-Binding Protein  
CML  Chronic Myeloid Leukemia 
CNS Central Nervous System 
CSF-I Colony-Stimulating Growth Factor I 
4E-BP 4E-Binding Protein 
EGF Epidermal Growth Factor 
ERK Extracellular Signal-Regulated Kinase 
FAB  French-American-British Classification 
FGF Fibroblast Growth Factor 
FKHR Forkhead 
FLT3 Fms-like Tyrosine Kinase 3 
FL  FLT3 Ligand 
FTI  Farnesyltransferase Inhibitor   
GBM  Glioblastoma Multiforme  
GPCR  G-Protein Coupled Receptor 
GSK-3 Glycogen Synthase Kinase-3 
IGF Insulin-like Growth Factor 
IGFBP1-6 Insulin-like Growth Factor Binding Protein 1-6 
IGF-IR Insulin-like Growth Factor I Receptor 
IR  Insulin Receptor 
IRS Insulin Receptor Substrates 
ITD Internal Tandem Duplication 
JAK  Janus Protein Tyrosine Kinase  
M-6-PR Mannose 6-Phosphate Receptor; IGF-II Receptor 
MB Medulloblastoma 
MDM-2 Murine Double Minute Gene 2 
PhD Thesis  Abbreviations 
VI 
MDS  Myelodysplastic Syndrome 
MM  Multiple Myeloma  
MPD  Myeloproliferative Disease  
MRT Malignant Rhabdoid Tumor 
mTOR Mammalian Target of Rapamycin 
NB Neuroblastoma 
PDGF Platelet-Derived Growth Factor 
PDK1 Phosphoinositide-dependent Kinase-1 
PI Phosphatidylinositol 
PI3K Phosphoinositide 3-Kinase 
PI(3)P Phosphatidylinositol-3-Monophosphate 
PI(3,4)P2 Phosphatidylinositol-3,4-Bisphosphate 
PI(3,4,5)P3; PIP3 Phosphatidylinositol-3,4,5-Trisphosphate 
PKB Protein Kinase B (also termed Akt) 
PTK Protein Tyrosine Kinase 
RA  Rheumatoid Arthritis 
????? Retinoic Acid Receptor Alpha  
Rheb Ras Homologue Enriched in the Brain 
RNAi RNA Interference 
RTK Receptor Tyrosine Kinase 
S6K Ribosomal Protein S6 Kinase 
SCLC Small Cell Lung Cancer 
Shc Src-Homology Collagen Protein 
shRNA Small Hairpin RNA 
SOS  Son of Sevenless 
STAT  Signal Transducer and Activator of Transcription 
TSC1, TSC2 Tuberous Sclerosis Complex 1 and 2 
 
 
 
 
 
 
 
 
PhD Thesis  Summary 
1 
1. A.  SUMMARY 
 
The acute myeloid leukemia (AML) is a quickly progressing, heterogeneous clonal disorder of 
hematopoietic progenitor cells. A significant progress in the understanding the pathogenesis of 
AML has been achieved in the past few years. Two major types of genetic events are thought to 
give rise to leukemic transformation: alterations in the activity of transcription factors controlling 
hematopoietic differentiation and activation of components of receptor tyrosine kinase (RTK) 
signaling pathways. This has led to the development of promising new therapeutic strategies for 
the disease. Recent developments in the field of molecularly targeted therapies for AML involve 
RTKs such as the FMS-like tyrosine kinase 3 (Flt3), c-Kit and signal transduction via the 
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. Initial 
results imply that targeting RTKs is a very promising approach for AML and that other receptors, 
such as the insulin-like growth factor receptor (IGF-IR), could also represent new targets in the 
future.  
 
The main goal of this work was therefore aimed at gaining deeper insight into RTK signaling in a 
panel of AML cell lines and patient blast cells. A broad potein expression analysis was set up in 
order to identify cancer-specific expression patterns of signaling molecules and to uncover 
potential molecular targets. Using different approaches the molecular function and the feasibility 
of targeting the candidate proteins was investigated. Novel specific inhibitors were tested and 
neutralizing antibodies and RNA interference (RNAi) were used to block or down-regulate the 
individual proteins. Our study of the IGF-IR/PI3K signaling system in AML cells uncovered a 
novel role for autocrine IGF-I signaling in the growth and survival of these cancer cells. Besides, 
we could show that targeting this signaling branch in combination with commonly used 
chemotherapeutical agents represents an interesting novel approach for AML therapy.  
As protein expression analysis revealed highly variable expression levels of the mammalian 
target of rapamycin (mTOR) in the panel of cells analyzed, further interest was laid on the role of 
mTOR in AML. Cells expressing low levels of mTOR were compared to cells expressing high 
levels of this protein and a siRNA screen was aimed at uncovering human kinases that modulate 
the sensitivity to the mTOR inhibitor rapamycin. Preliminary results suggest that mTOR plays a 
crucial role in cell growth and survival in a subset of AML cells and that rapamycin in 
combination with certain RTK or Syk/ZAP70 inhibitors has potential for AML therapy. 
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Another study investigating RTK signaling in childhood central nervous system (CNS) tumors 
revealed autocrine insulin production by the cancer cells and a crucial role of this growth factor 
and the insulin receptor (IR)/PI3K signaling pathway for cellular growth and survival of the 
malignant cells.   
 
Moreover, our interest was set on elucidating the specific role of individual PI3K isoforms in 
human cancer. The PI3Ks are a family of lipid kinases which transduce signals from RTKs and 
play a crucial role in a variety of intracellular signaling events including the control of cell 
growth and survival. Nevertheless, the specific functions of the individual isoforms in human 
cancer has not been completely understood yet. In view of the search for specific molecular 
targets for cancer therapy, an extensive knowledge of the exact role and function of these 
signaling enzymes is of high importance. Therefore, PI3K isoforms were specifically targeted in 
human cancer cells and the effect on cellular responses was investigated. In AML, a predominant 
role of the class IA PI3Ks p110β and p110δ for cell growth, survival and chemo-resistence could 
be described. In an extensive study of PI3K isoforms in human neuroblastoma, a novel function 
of p110δ in growth and survival of this type of cancer could be identified. Since much less 
attention has been paid to the role of the class II PI3Ks in human cancer, our work was aimed at 
elucidating the expression pattern and function of PI3KC2β in a panel of human tumor cells 
including AML, different brain tumors and neuroendocrine tumors. Novel isoform-specific 
inhibitors were tested and with the use of RNAi it could be shown that PI3KC2β contributes to 
cell survival, proliferation and migration of various human cancer cells.  
 
In summary, our study of the RTK/PI3K signaling system in distinct human cancers has provided 
novel insights into the importance and the complexity of this network for tumor growth and 
survival. Moreover, the analysis of specific components of this crucial signaling network has 
uncovered potential molecular targets for future cancer therapy.   
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1. B.  ZUSAMMENFASSUNG 
 
Die akute myeloide Leukämie (AML) ist eine bösartige monoklonale Krankheit der 
hämatopoitischen Vorläuferzellen mit einem rasch progredienten klinischen Verlauf. Hinsichtlich 
der Ätiopathogenese konnten aber in den letzen Jahren wichtige neue Erkenntnisse gewonnen 
werden, so so dass man heute v.a. von zwei essentiellen genetischen Veränderungen ausgeht, die 
hauptsächlich zur Entstehung dieser Krebsart beitragen: 1) Veränderungen in der Aktivität von 
Transkriptionsfaktoren, welche die Differenzierung der hämatopoitischen Zellen kontrollieren, 
sowie 2) die Aktivierung von Komponenten des Rezeptor-Tyrosinkinase (RTK)-Signalweges. 
Diese Faktoren stellen eine wichtige Grundlage für die Entwicklung neuartiger Strategien in der 
Krebstherapie dar. Aktuelle Errungenschaften im Gebiet der zielgerichteten AML-Therapien 
fokusieren bereits auf RTKs. Zudem gibt es Studien, welche zum Beispiel die FMS-like tyrosine 
kinase 3 (FLT3), c-Kit oder die Signalübermittlung via phosphoinositide 3-kinase (PI3K) und die 
mitogen-activated protein Kinase (MAPK) als molekulares Ziel beschreiben. Erste Resultate 
zeigen auch, dass die RTKs als therapeutisches Ziel eine sehr erfolgversprechende Strategie 
darstellen. Eine Vielzahl weiterer Kandidaten aus dieser Gruppe - wie zum Beispiel der insulin-
like growth factor receptor (IGF-IR) - wird gegenwärtig in vitro sowie in präklinischen Studien 
untersucht .  
 
Der Hauptfokus meiner Doktorarbeit lag daher im detaillierten Studium der Signalübermittlung 
durch RTKs in verschiedenen AML-Zelllinien und Vorläuferzellen (Blasten) von AML-
Patienten. Eine ausführliche Analyse galt dabei der Expression von verschiedenen Proteinen, 
welche eine Rolle in der intrazellulären Signalübertragung spielen, um so ein ein spezifisches 
Musters für Krebszellen zu identifizieren. Mit Hilfe von verschiedenen Techniken wurde dann 
die genaue molekulare Funktion der Kandidaten untersucht und ihr Potential als therapeutisches 
Ziel analysiert. Schliesslich wurden neue, spezifische Inhibitoren getestet und neutralisierende 
Antikörper und RNA-Interferenz (RNAi) zur zielgerichteten Hemmung der gewünschten 
Proteine angewendet.  
Eine umfangreiche Analyse des IGF-IR/PI3K Netzwerkes in AML-Zellen zeigte insbesondere, 
dass die leukämischen Zellen in der Lage sind, IGF-I selber zu produzieren und zu sezernieren. 
Damit konnte eine neue, autokrine Rolle von IGF-I für das Wachstum und Überleben der 
Krebszellen beschrieben werden. Zugleich konnten wir zeigen, dass dieses System ein 
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vielversprechender molekularer Angriffspunkt in der Krebstherapie ausmacht, v.a. in 
Kombination mit klinisch bereits eingesetzten Chemotherapeutika.  
Daneben zeigte die Analyse der Proteinexpression in AML-Zellen eine ausgeprägte Variabilität 
des mammalian target of rapamycin (mTOR). In einem nächsten Schritt haben wir  deshalb die 
funktionelle Rolle von mTOR in AML weiter untersucht. Dabei wurden Zelltypen mit einer 
starken Expression von mTOR gegenüber einer geringen mTOR-Expression verglichen. Mittels 
eines siRNA-screens suchten wir zudem nach Kinasen, welche die Sensitivität zum mTOR 
Inhibitor Rapamycin beeinflussen. Erste Resultate zeigten, dass mTOR eine wichtige Rolle für 
das Wachstum und Überleben in einer Gruppe von AML Zellen spielt und dass Rapamycin in 
Kombination mit gewissen RTK oder SYK/ZAP70 Inhibitoren als mögliche neue Therapeutika 
der AML in Frage kommen.      
 
In einer anderen Studie konnten wir zeigen, dass in pädiatrischen Tumoren des 
Zentralnervensystems (ZNS) die autokrine Produktion von Insulin eine essentielle Rolle für das 
Wachstum und Überleben der Krebszellen spielt. 
 
Des Weiteren wurde die spezifische Funktion der verschiedenen PI3K Isoformen in Krebs 
untersucht. Die PI3Ks bilden eine Familie von Kinasen, welche als wichtige Mediatoren von 
intrazellulären Signalen eine Vielfalt von zellbiologischen Vorgängen kontrollieren, in erster 
Linie aber Wachstum und Überleben der Zelle. Dennoch fehlen bis heute weitgehend Studien, 
welche die verschiedenen PI3K-Isoformen nach ihrer spezifischen Relevanz untersucht haben. 
Die Suche nach geeigneten molekularen Zielen für die Krebstherapie stellt jedoch unumgänglich 
eine fundierte Kenntnis der exakten Funktion von potentiellen Kandidaten dar. Daher haben wir 
spezifische PI3K-Isoformen untersucht und ihre Rolle in zellulären Antworten analysiert. In 
AML konnten so die PI3K-Isoformen p110δ und p110β als wichtigste Isoformen für Wachstum 
und Überleben der Krebszelle sowie deren Resistenz gegenüber Chemotherapeutika identfiziert 
werden. Diese Daten konnten zudem in einer Analyse von PI3K-Isoformen in Neuroblastomen 
bestätigt werden. Da der Rolle von PI3Ks der Klasse II in Krebszellen bis heute noch kaum 
Beachtung geschenkt wurde, haben wir eine umfangreiche Studie zur Expression und Funktion 
von PI3KC2β in verschiedenen Krebsarten (AML, Hirntumoren und neuroendokrine Tumoren) 
durchgeführt. Es wurden neue Isoform-spezifische Inhibitoren getestet und mittels RNAi konnte 
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gezeigt werden, dass PI3KC2β zum Überleben und Wachstum, wie auch zur Migration von 
Krebszellen beiträgt.      
 
Zusammengefasst gibt die vorliegende Dissertation bedeutende Einblicke in die Komplexität des 
RTK/PI3K Netzwerkes und unterstreicht die Wichtigkeit dieses Signalsystemes für das 
Wachstum und Überleben von Krebszellen. Zudem konnten durch die fundierte Untersuchung 
von einzelnen Komponenten dieses Systemes neue potentielle Ziele zur Krebstheapie identifiziert 
werden. 
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2. INTRODUCTION 
 
2.1. Acute Myeloid Leukemia 
 
Acute leukemias represent a small (<3%) fraction of all human cancers, but are a leading cause of 
cancer-related mortality in children and young adults (Deschler & Lubbert, 2006; Kolitz, 2006). 
The acute myeloid leukemia (AML) accounts for about 25% of all leukemias in adults in the 
Western world, and is the second most frequent form of leukemia following chronic lymphocytic 
leukemia (CLL) (Deschler & Lubbert, 2006). The incidence of AML is 3.4 cases per 100,000 
general population. AML is a heterogeneous group of diseases characterized by uncontrolled 
clonal proliferation of hematopoietic precursor cells leading to impairment of normal 
hematopoietic cell production, causing cytopenias. Based on the cell type of which the leukemia 
cell developed together with the degree of its maturity, the French-American-British (FAB) 
classification system groups AML into eight subtypes, M0 through M7 (Table 1). The different 
subtypes are known to have varying clinical prognoses and therapy responses.  
 
French-American-British Classification (FAB) 
M0 undifferentiated AML 
the bone marrow cells show no significant signs of differentiation 
M1 myeloblastic leukemia, without differentiation 
the bone marrow cells show minimal signs of maturation (granulocyte differentiation) 
M2 myeloblastic leukemia, with differentiation 
the bone marrow cells are at or beyond the promyelocyte stage (early granulocyte) 
M3 promyelocytic leukemia 
most cells are abnormal early granulocytes between the stage of myeloblasts and 
myelocytes 
M4 myelomonocytic leukemia 
variable amounts of differentiated granulocytes and monocytes in the bone marrow and 
circulating blood; > 20% monocytes and promonocytes in the bone marrow 
M5 monoblastic or monocytic leukemia 
poorly differentiated monoblasts (immature monocytes) with lacy-appearing genetic 
material or large population of monoblasts, promonocytes, and monocytes 
M6 erythroleukemia  
abnormal red blood cell-forming cells making up over half of the nucleated cells in the 
bone marrow 
M7 megakaryoblastic leukemia 
immature megakaryocytes or lymphoblasts 
 
Table 1: French-American-British Classification of AML 
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The World Health Organization Classification (WHO) subdivides the AMLs into 4 major 
categories: AML with recurrent cytogenetic translocations; AML with multilineage dysplasia; 
AML and myelodysplastic syndromes (MDS), therapy-related; and AML not otherwise 
categorized (Table 2). This system provides prognostic information in terms of cytgenetic 
findings and associated myelodysplastic changes in the AML.  
 
World Health Organization Classification (WHO) 
AML with recurrent 
cytogenetic translocations 
t(8;21)(q22;q22) AML1/CBFα/ETO 
t(15;17)(q22;q12) and variants PML/RARα 
inv(16)(p13;q22) 
t(16;16)(p13;q22) CBFβ/MYH1 
11q23 MLL abnormalities 
Patients generally have a high rate of remission and a better 
prognosis compared to other types of AML.  
AML with multilineage 
dysplasia 
Myelodysplastic syndrome (MDS) or myeloproliferative disease 
(MPD) that transformed into AML. Occurs often in elderly 
patients and often with a worse prognosis. 
AML and MDS, therapy-
related 
AML or MDS developed after chemotherapy and/or radiation 
therapy. Often characterized by specific chromosomal 
abnormalities and often with a worse prognosis. 
AML not otherwise 
categorized 
AML subtypes that do not fall into the above categories. 
 
Table 2: World Health Organization Classification of AML 
 
During the past decade, there has been a shift in AML diagnosis, classification, and treatment 
strategies from protocols relying on cell morphology and cytochemistry, to cell-surface antigen 
expression and the use of cytogenetic and molecular markers. Treatment of AML, however, still 
represents a difficult challenge because of relapse and complications associated with treatment 
(Kolitz, 2006). In the past 40 years, advances in supportive care and development of 
chemotherapeutic agents have led to improved outcomes in patients with acute myeloid leukemia. 
High relapse rates following remission have led to extensive efforts to develop techniques and 
regimens for detecting and eliminating minimal residual disease. Since standard cytotoxic 
chemotherapies have side effects to which AML patients, especially those of advanced age, are 
susceptible, there is a need to develop new therapies to overcome these difficulties (Deschler & 
Lubbert, 2006; Estey & Dohner, 2006). A better understanding of the biology and the molecular 
pathogenesis of AML has led to the development of new, targeted agents and strategies for AML 
treatment. Targeted therapy has indeed improved outcomes in some AML patients. Most of the 
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new agents used for AML therapy are less toxic then their predecessors, and combinations with 
more intensive traditional regimens are being tested. 
 
2.1.1. Pathogenesis 
Great efforts have been made to gain a better understanding of the molecular pathogenesis of 
AML. The malignancy is characterized by an accumulation of granulocyte or monocyte 
precursors in the blood. This is caused by the clonal growth of immature progenitor cells, which 
display increased proliferation and resistance to apoptosis, as well as impaired differentiation 
(Steffen et al., 2005).  
Recurring chromosomal translocations are a hallmark of human leukemias. There are more than 
300 recurring chromosomal translocations, of which more than 100 have been cloned (Kelly & 
Gilliland, 2002), providing important insights into the pathogenesis of the disease. Chromosomal 
aberrations are found in about half of all AML cases and are grouped into two major subtypes: 
balanced and unbalanced aberrations (Hiddemann et al., 2005). The biology of AML with 
balanced chromosomal translocations is fairly well understood, in contrast to the situation in 
AML with unbalanced aberrations (Hiddemann et al., 2005). Moreover, nearly half of all AML 
cases present a non-aberrant karyotype (Frohling et al., 2005; Hiddemann et al., 2005). In this 
category of AML, molecular analyses have revealed mutations in the FLT3, CEBPA, KIT and 
NPM genes, as well as MLL partial tandem duplication (Frohling et al., 2005; Hiddemann et al., 
2005).  
In AML, chromosomal translocations often result in loss-of-function mutations in transcription 
factors that are required for normal hematopoietic development (Kelly & Gilliland, 2002; Steffen 
et al., 2005; Tenen, 2003). The elucidation of the structure and function of leukemogenic genes, 
as well as the analysis of their occurrence in leukemia has led to a two-hit model of AML 
pathogenesis. According to this model, AML develops as a result of the concurrent emergence of 
two classes of genetic alterations (mutations or gene rearrangements). While class I mutations 
confer a proliferative and/or survival advantage to hematopoietic progenitors (Kelly & Gilliland, 
2002; Steffen et al., 2005), class II mutations lead to impaired hematopoietic differentiation. The 
increase in cell proliferation and survival of leukemic blasts (class I mutations) is thought to be 
caused by alterations in receptor tyrosine kinase (RTK) signaling pathways. In this context,  it 
has been demonstrated that mutations in FMS-like tyrosine kinase 3 (Flt3), c-Kit and Ras are 
frequent in AML (Kelly & Gilliland, 2002; Steffen et al., 2005). The activation status of growth 
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and survival pathways including phosphoinositide 3-kinase (PI3K)/Akt has also been found to be 
increased in AML blasts (Martelli et al., 2006). The impaired differentiation of AML blasts (class 
II mutation) is thought to occur through alterations in transcription factors required for normal 
myeloid  cell differentiation (Kelly & Gilliland, 2002; Steffen et al., 2005; Tenen, 2003). In 
AML, these transcription factors are frequently the target of translocations, leading to the 
expression of fusion proteins such as AML1/ETO, CBFβ/SMMHC, PML-RARα, or MLL fusion 
proteins (Kelly & Gilliland, 2002; Steffen et al., 2005).  
 
2.1.2. Genetic Alterations Involving Transcription Factors 
Transcription factors are frequently targeted by balanced chromosomal translocations in AML. 
These include core binding factor (CBF), retinoic acid receptor??????????????????? ??????????
the HOX family of transcription factors (Kelly & Gilliland, 2002; Steffen et al., 2005; Tenen, 
2003). Transcriptional coactivators, such as Creb-binding protein (CBP), p300, MOZ, TIF2, and 
MLL, are also targets of chromosomal translocations in AML (Kelly & Gilliland, 2002; Steffen 
et al., 2005). The targeted transcription factors are thought to be important for normal 
hematopoietic development. The consequence of the chromosomal translocations found in AML 
is loss-of-function and therefore impaired hematopoietic differentiation. For example, CBF is a 
heterodimeric transcription factor composed of a DNA-binding component, AML1, and the 
CBFß subunit which functions as a transcriptional activator of AML1. CBF controls the 
expression of genes that are critical for normal hematopoietic development. The three most 
common translocations involving CBF are the t[8;21], inv[16], and t[12;21] that result in 
expression of the AML1/ETO, CBFß/SMMHC, and TEL/AML1 fusion proteins, respectively. 
Each of these fusion proteins is a dominant negative inhibitor of CBF-mediated transcription. 
Transcriptional repression of CBF target genes by CBF-related fusion proteins is thought to be 
mediated through aberrant recruitment of the nuclear corepressor/histone deacetylase complex. 
??????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????
protein results in a block of differentiation at the promyelocyte stage caused in part by the 
recruitment of the nuclear corepressor complex. This block is relieved by all-trans-retinoic acid 
(ATRA), which induces the release of the nuclear corepressor complex by binding to 
??????????????????????????????  direct inhibitory effects on transcriptional activation, the fusion 
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proteins may also have additional roles in impairment of hematopoietic differentiation (Kelly & 
Gilliland, 2002).  
Interestingly, in hematological clonal disorders in children with Down Syndrome (DS), mutations 
are commonly found in the gene encoding the transcription factor GATA-1 (Wechsler et al., 
2002). The incidence of childhood acute leukemia is highly increased in children with DS, with a 
prevalence of acute megakaryoblastic leukemia (FAB M7) (Kurkjian et al., 2006). GATA-1 is 
known to be critical for normal development of erythroid and megakaryocyitc lineages, and the 
absence of GATA-1 promotes the accumulation of immature megakaryocytes (Magalhaes et al., 
2006). The fact that mutations in GATA-1 occur in nearly every case of DS with a 
myeloproliferative disorder suggests that deregulation of GATA-1 is an essential step in the 
development of the disease in this particular patient group (Gurbuxani et al., 2004). Even though 
a direct link between trisomy 21 and the X-linked transcription factor GATA-1 have not been 
found so far, models including gene dosage effects have been proposed and trisomy 21 is thought 
to cooperate with the non- or dysfunctional GATA-1 in the multistep process in which progenitor 
cells acquire multiple genetic lesions (Gurbuxani et al., 2004).   
 
 
2.2. Receptor Tyrosine Kinase Signaling 
 
Receptor tyrosine kinases (RTKs) are central components of cell signaling networks and play a 
crucial role in normal physiological processes such as in embryogenesis and development. RTK 
networks control fundamental cellular activities including cell proliferation and survival, cell 
cycle control, metabolism, as well as cell shape and movement. They are able to detect, filter, and 
process a variety of environmental and intercellular factors. Numerous membrane spanning 
surface receptors have been identified and classified based on ligand preference, the induction of 
biological responses and their primary structure. Protein tyrosine kinases (PTKs) are endowed 
with intrinsic protein kinase activity that catalyzes the transfer of γ-phosphate of ATP to tyrosine 
residues of protein substrates (Hubbard et al., 1998). The receptor tyrosine kinases (RTKs) are 
one large family of PTKs that contain an intracellular catalytic protein tyrosine kinase domain, an 
extracellular ligand binding domain and regulatory sequences. More than 50 mammalian RTKs 
are known so far including the well known insulin receptor (IR), Fms-like tyrosine kinase 3 
(FLT3), c-Kit, epidermal growth factor (EGF), platelet derived growth factor (PDGF), fibroblast 
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growth factor (FGF), colony-stimulating growth factor I (CSF-I) and insulin-like growth factor I 
(IGF-I) receptor (Hunter, 1998). A plethora of ligands such as peptides, proteins, lipids, or 
carbohydrates bind to and regulate the pleiotropic actions of RTKs. Tight control of the receptor 
activity is maintained by protein-tyrosine phosphatases, by other serine/threonine kinases, as well 
as autoregulatory mechanisms in the receptors. The extracellular binding of a specific ligand to a 
RTK induces conformational alterations that are translated across the membrane barrier resulting 
in the activation of its intracellular kinase activity (Schlessinger, 1988). In general, ligand binding 
induces allosteric interactions causing dimerization of receptor subunits through disulfide-bridges 
(Riedel et al., 1989) and autophosphorylation of specific tyrosine residues within their 
cytoplasmatic domains (Jiang & Hunter, 1999; Schlessinger, 1988). Dimerization-mediated 
receptor activation mechanisms have been described for receptors composed of heterotetrameric 
structures such as the IR, IGF-IR, PDGFR and the EGFR. Tyrosine autophosphorylation 
stimulates the intrinsic kinase activity of the receptor and leads to the generation of recruitment 
sites for downstream signal transducers. Src homology-2 (SH2) (Schaffhausen, 1995) or 
phosphotyrosine-binding (PTB) (Zhou & Fesik, 1995) domains are known phosphotyrosine-
recognition domains present in various signaling proteins. 
Activation of RTKs leads to rapid stimulation of phosphatidylinositol metabolism and the  
generation of multiple second messengers. One well characterized signaling pathway downstream 
of the IR and IGF-IR involves the insulin receptor substrates-1 to -4 (IRS-1 to -4) and the Src-
homology collagen protein (Shc) isoforms as adapter molecules. The adapter proteins bind to the 
phosphotyrosine residues within the juxtamembrane region of the cytoplasmatic receptor and 
undergo subsequent tyrosine phosphorylation. Phosphorylation of the IRS adapter molecules on 
one hand triggers activation of the phosphoinositide 3-kinase (PI3K)/Akt signaling pathway 
(Myers et al., 1993; Vanhaesebroeck et al., 1997a; Yamamoto et al., 1992), whereas, on the other 
hand, the Shc adapter activates signaling by the Ras/Raf/MAPK pathway (reviewed in 
(Vanhaesebroeck et al., 1997a)). Generally, signals transduced through those signaling cascades 
have pleiotropic effects on cell behavior controlling cell proliferation, differentiation and cell 
migration, as well as apoptosis (Peruzzi et al., 1999). The PI3Ks phosphorylate 
phosphatidylinositol (PI) on the D-3 position of the inositol ring, producing distinct second 
messengers such as PI(3)P, PI(3,4)P2 and PI(3,4,5)P3 (PIP3) (Katso et al., 2001). These lipid 
products activate signal transduction by diverse proteins including phosphoinositide-dependent 
kinase-1 (PDK1), forkhead (FKHR), glycogen synthase kinase-3 (GSK-3), tuberous sclerosis 
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complex 1 and 2 (TSC1, TSC2), BAD, Ras homologue enriched in the brain (Rheb), mammalian 
target of rapamycin (mTOR), 4E-binding protein (4E-BP) and ribosomal protein S6 kinase (S6K) 
(Katso et al., 2001). The Ras/Raf/extracellular signal-regulated kinase (Erk) cascade proceeds 
from Ras and its downstream effector Raf to Erk (p42/44 MAPK) (Seger & Krebs, 1995).  
 
Fig. 1: Overwiew of RTK signaling. Signals are transduced via the mitogen-activated protein kinase (MAPK) or the 
phosphoinositide 3-kinase (PI3K) pathway. Key upstream regulators of MAPK signaling include growth factor 
receptor-bound protein 2 (Grb2), Son of Sevenless (SOS), Ras, Raf, MAPK/Erk kinase (MEK), extracellular signal-
regulated kinase (ERK) and ELK1. Activation of the PI3K pathway is initiated by recruitment of the PI3K complex 
to the phosphorylated receptor. Downstream signals are transduced via phosphoinositide-dependent kinase 1 
(PDK1), protein kinase B/Akt (AKT), the mammalian target of rapamycin (mTOR), 4E-binding protein (4E-BP) and 
ribosomal protein S6 kinase (S6K), forkhead (FKHR), BAD and glycogen synthase kinase-3 (GSK3).  
 
Protein tyrosine phosphorylation was discovered more than 25 years ago (Hunter & Sefton, 1980) 
and protein tyrosine kinases, the signaling pathways they activate, as well as the mechanisms 
underlying their action and regulation have been widely studied. The importance of 
understanding the complexity of signaling networks, their regulation and the RTK 
interconnections has been highlighted by a large variety of molecular alterations and 
deregulations found in various human diseases including cancer.  
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2.2.1. Insulin-like Growth Factor I Receptor Signaling  
The Insulin/IGF family of cell signaling factors comprises a phylogenetically conserved system 
with a critical role in growth and development of many tissues and the regulation of overall 
growth and metabolism. A high complexity is achieved by tight regulation of multiple proteins 
including three receptors (insulin receptor (IR), insulin-like growth factor I receptor (IGF-IR), 
and IGF-II/mannose 6-phosphate receptor (M-6-PR)), three ligands (insulin, IGF-I, and IGF-II), 
and six known types of circulating binding proteins (insulin-like growth factor binding proteins 
1-6 (IGFBP1-6)) (De Meyts et al., 1994; Jones & Clemmons, 1995; Lee & Pilch, 1994). The 
IGF-IR is a transmembrane tyrosine kinase widely expressed in many human tissues and cell 
types with high homology to the IR. However, experimental data suggest distinct roles for these 
two receptors, namely control of cell growth, differentiation and apoptosis by the IGF-IR and the 
regulation of physiological processes by the IR (Blakesley et al., 1996; Patti & Kahn, 1998; Urso 
et al., 1999).  
The IGF-IR is a heterotetrameric glycoprotein composed of two alpha and two beta subunits, 
post-transcriptionally linked by disulfide bonds (alpha2beta2). The alpha chain is extracellular,  
while the beta chain is composed of a short extracellular region, a single transmembrane domain, 
and a cytoplasmatic portion harboring the catalytic tyrosine kinase domain flanked by two 
regulatory regions and a juxtamembrane region that serves as a docking site for signaling 
molecules (Hubbard & Till, 2000). Activation of the receptor is achieved by binding of the 
specific ligand to the extracellular alpha subunit, triggering autophosphorylation of three tyrosine 
residues within the kinase domain of the beta subunit (Kato et al., 1993; Murakami & Rosen, 
1991).  
IGF-I and IGF-II are single-chain polypeptides with sequences 62% identical to pro-insulin. 
However, they are not proteolytically cleaved but remain linked in their mature form as four 
peptide domains (Daughaday & Rotwein, 1989; LeRoith et al., 1993). Unlike other peptide 
hormones, the production and storage of these growth factors is not organ- or cell type-restricted, 
even though the main fraction originates from the liver. Instead, IGFs may be produced by almost 
any human cell (Rosen, 1999). The half-lives, transportation and bioavailability of the IGFs 
circulating at high concentrations in the bloodstream and extracellular fluids are modulated by 
several high affinity IGFBPs (IGFBP1-6). More than 99% of the circulating IGFs is bound to 
IGFBPs or can be found in a ternary complex with IGFBPs and a third component, the acid-labile 
subunit (ALS) (Baxter, 1988). The IGFBP themselves are tightly regulated by tissue specificity, 
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cell or matrix association, phosphorylation and proteolysis by various proteases (Baxter, 2000; 
Ferry et al., 1999).  
Both IGF-I and IGF-II interact with the IGF-IR, although IGF-I shows a much higher affinity 
than IGF-II. The closely related insulin, the main ligand for the IR, has an IGF-IR-binding 
affinity which is less than 1% of that of IGF-I (Denley et al., 2004). The intrinsic receptor for 
IGF-II, the M-6-PR, differs significantly from the IGF-IR, possesses no tyrosine kinase activity 
and was reported to target IGF-II for lysosomal degradation, without inducing a specific cell 
response (Kornfeld, 1992).  The ability of the highly homologous IGF-IR and IR to form hybrid 
receptors by dimerization of their hemi-receptors further increases the complexity of the 
signaling system. Such IGF-IR/IR hybrid receptors have been reported to influence cell responses 
by altering the affinities of their growth factor ligands  (Pandini et al., 2002).  
The activated auto-phosphorylated IGF-IR undergoes major conformational changes, providing 
docking sites for the recruitment of substrate proteins in order to initiate intracellular signaling 
cascades. The so far best characterized signaling pathways involve the insulin receptor substrates-
1 to -4 (IRS-1 to -4) and the Src-homology collagen protein (Shc) isoforms as adapter substrates. 
The adapter proteins bind to specific phosphotyrosine residues within the juxtamembrane region 
of the cytoplasmatic IGF-IR and undergo subsequent tyrosine phosphorylation. Phosphorylation 
of the IRS adapter molecules on one hand triggers activation of the PI3K/Akt signaling pathway 
(Myers et al., 1993; Vanhaesebroeck et al., 1997a; Yamamoto et al., 1992), whereas, on the other 
hand, the Shc adapter activates signaling by the Ras/Raf/MAP-kinase pathway (reviewed in 
(Vanhaesebroeck et al., 1997a)). Generally, signals controlled by the IGF-IR have pleiotropic 
effects on cell behavior controlling  cell proliferation, differentiation and cell migration, but also 
regulating the apoptotic machinery (Peruzzi et al., 1999).  
 
2.2.1.1. The Role of the IGF-IR in Human Cancer 
In recent years, a growing body of evidence has arisen, suggesting a key role for IGF signaling in 
various types of human cancer. Since the signals emanating from activated IGF-IR regulate cell 
proliferation, survival, differentiation and transformation, mechanistic studies have been aimed at 
defining the role(s) of this receptor in the neoplastic phenotype. While the involvement of the 
IGF-IR in stimulating cell proliferation was an early finding, a number of studies performed in 
the last two decades have included experiments aimed at investigating the role of this receptor in 
the transformation of cells, as well as in metastatic events. Over-expression of the IGF-IR in NIH 
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3T3 cells lead to a fully transformed phenotype, including anchorage-independent growth and 
loss of contact inhibition, as well as rapid tumor formation in nude mice (Kaleko et al., 1990). 
More recently, a novel animal model was generated, involving transgenic expression of a fusion 
receptor that is constitutively activated by homodimerization (Carboni et al., 2005). The fusion 
gene was placed under the control of the mouse mammary tumor virus promoter, which drives 
transcription in the mammary and salivary glands of transgenic mice. The incidence and kinetics 
of tumor emergence in these animals suggest that the transgene is sufficient to initiate and 
maintain the transformation process. Transfection of a cell line established from a salivary gland 
adenocarcinoma with small interfering RNAs against the IGF-IR resulted in a 50% reduction in 
thymidine incorporation, emphasizing the effect of deregulated signaling via the IGF-IR on cell 
proliferation (Carboni et al., 2005). Alternatively, other studies have investigated the effect of 
decreased IGF-IR signaling. Mouse embryo fibroblasts (MEFs) homozygous for a targeted 
disruption of the Igfr1 gene showed slower growth than wild-type cells in serum-containing 
medium and failed to form colonies in soft agar, even when stably transfected with activated Ras, 
a crucial downstream signaling mediator (Sell et al., 1994). Another approach to study impaired 
IGF-IR signaling was the generation of LCC6 cells, a metastatic variant of a breast cancer cell 
line, expressing a C-terminally truncated IGF-IR, which acts as a dominant-negative receptor 
(Sachdev et al., 2004). These cells showed decreased activation of downstream mediators, such 
as IRS-1 and IRS-2, as well as Akt. While proliferative responses of these cells to IGF-I or serum 
were not affected in vitro, they showed decreased anchorage-independent growth. Furthermore, 
analysis of xenograft tumor growth revealed that in contrast to wild-type cells, cells expressing 
the dominant-negative IGF-IR did not metastasize to the lungs, although they were equally 
aggressive locally when compared to wild-type cells (Sachdev et al., 2004).  
While no cancer-specific mutations of the IGF-IR or its ligands have been described to date, a 
plethora of studies have provided evidence for a link between this signaling pathway and the risk 
of developing cancer (reviewed in (Khandwala et al., 2000)). The most common findings 
associated with deregulated IGF signaling are over expression of the IGF-IR or the establishment 
of autocrine or paracrine signaling loops (Table 1). While high expression levels of the IGF-IR 
have been found in breast and colorectal cancer (Nielsen et al., 2004; Peters et al., 2003), 
autocrine signaling loops are a more common phenomena, and have been reported in a wide 
variety of human malignancies (Guo et al., 1995; Nakanishi et al., 1988; Ohmura et al., 1990). 
Paracrine signaling has mainly been described for breast cancer, where stromal cells have been 
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shown to produce IGF-I and IGF-II (Gebauer et al., 1998; Yee et al., 1989). Population studies 
have further highlighted the importance of IGF signaling in some of the most common cancers. 
The most readily accessible components of the IGF signaling pathway are IGF-I, IGF-II and the 
IGFBPs, as their circulating concentrations can easily be determined from blood samples. It is 
important to mention that circulating IGF-I levels vary substantially between normal individuals 
(Greenspan & Gardner, 2001). Nevertheless, evidence from epidemiological studies has revealed 
a correlation between elevated IGF-I levels and an increased risk of cancer diagnosis (reviewed 
in (Pollak et al., 2004)). Although the population studies did not always come to the same 
conclusions, a recent systematic review of these results led to the interpretation that circulating 
IGF-I levels are indeed related to a risk of several common cancers (Renehan et al., 2004). The 
most significant correlation between increased levels of IGF-I and the risk of cancer diagnosis 
was found for prostate cancer and colorectal cancer (Chan et al., 2002; Giovannucci et al., 2000; 
Harman et al., 2000; Kaaks et al., 2000; Ma et al., 1999; Palmqvist et al., 2002; Stattin et al., 
2000; Wolk et al., 1998). The majority of the studies observed that individuals with elevated 
levels of IGF-I had an increased risk of developing cancer. It is important to emphasize that the 
increases detected were modest, and therefore were not always confirmed in population studies, 
especially if cohort sizes were small (Lacey et al., 2001; Renehan et al., 1999). In the case of 
breast cancer, elevated levels of IGF-I have only been associated with an increased risk for 
premenopausal women, while no association between circulating levels and cancer risk was 
found for postmenopausal women (Hankinson et al., 1998; Keinan-Boker et al., 2003; Krajcik et 
al., 2002; Toniolo et al., 2000). Although elevated levels of IGF-I were detected in patients newly 
diagnosed with lung cancer (Yu et al., 1999), population studies were not able to confirm a direct 
link between plasma levels and cancer risk (London et al., 2002; Lukanova et al., 2001; Spitz et 
al., 2002). A possible explanation for this inconsistency is the strong influence of carcinogen 
exposure (e.g. cigarette smoking or asbestos) on the development of lung cancer. 
Growth hormone (GH), produced in the pituitary, stimulates production of IGF-I. In patients with 
acromegaly, where GH levels are increased, retrospective studies suggest that GH hypersecretion 
modifies the progression of existing malignancies, particularly colon cancer (Orme et al., 1998; 
Webb et al., 2002). A study performed on GH-treated cancer survivors found no increased risk of 
disease recurrence or death in these patients. While the overall incidence of secondary 
malignancies was not increased, survivors of acute leukemia and lymphoma had an elevated 
number of secondary solid malignancies (Sklar et al., 2002). The relatively marginal effect of 
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GH/IGF excess on tumor onset and progression might indicate that the auto- and paracrine 
component of the mechanism is more important than the endocrine.  
In summary, both mechanistic as well as epidemiological studies have provided valuable 
information concerning the role of IGF signaling in human cancers. Since this signaling pathway 
regulates essential processes such as cell proliferation, survival or differentiation, it might 
provide targets for the development of promising new therapeutic approach, which could 
possibly be combined with other classical treatment regimens.    
 
2.2.2. Phosphoinositide 3-Kinases 
The PI3Ks are a family of evolutionary conserved lipid kinases, playing a crucial role in 
controlling a wide variety of intracellular signaling events. PI3Ks phosphorylate 
phosphatidylinositol (PI) on the D-3 position of the inositol ring, producing distinct second 
messengers such as PI(3)P, PI(3,4)P2 and PI(3,4,5)P3 (PIP3) (Katso et al., 2001). These lipid 
products are known to activate diverse target proteins involved in complex signaling cascades, 
ultimately resulting in the activation of cellular activities comprising cell growth, proliferation, 
survival and motility.  
The family of PI3Ks identified in various species can be subdivided into three main classes (class 
I-III), based on structural similarity and in vitro substrate specificity (Katso et al., 2001) 
(overview given in Fig. 2). Class IA includes p110α, p110β, and p110δ, known to form a 
heterodimeric complex with a p85, p55, or p50 (α or β) regulatory subunit. This adapter subunit 
contains two SH2 domains mediating their association with activated tyrosine kinase-coupled 
growth factor receptors (Katso et al., 2001). PIP3 produced by class IA PI3Ks activates the protein 
kinase phosphoinositide-dependent protein kinase-1 (PDK1), inducing the recruitment and 
activation of the key signal transducer protein kinase B (PKB)/Akt (Vanhaesebroeck & Alessi, 
2000). Akt is involved in the regulation of the cell cycle and glucose metabolism through 
glycogen synthase kinase-3 (GSK-3) (Liang & Slingerland, 2003) and the modulation of cell 
growth and survival, as well as the control of the translational machinery through the mammalian 
target of rapamycin (mTOR), the ribosomal protein S6 kinase (S6K) and the 4E-binding protein 
(4E-BP) (Fingar & Blenis, 2004). Downstream events controlled by Akt further include the 
control of apoptosis through the regulation of proteins such as forkhead (FKHR), BAD, NF-κB 
and murine double minute gene 2 (MDM-2) (Downward, 2004) (overview given in Fig. 1). 
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Expression studies of the class IA PI3K isoforms have pointed out an ubiquitous distribution of 
the subunits p110α and p110β in all human tissues, whereas p110δ is preferentially expressed in 
leukocytes (Chantry et al., 1997; Vanhaesebroeck et al., 1997a; Vanhaesebroeck et al., 1997b).  
The class IB PI3Ks is made up of one enzyme only, p110γ, which functions through heterodimer 
formation with a regulatory subunit p101 (Krugmann et al., 1999) or p84 (Suire et al., 2005). 
Activation of p110γ is controlled by receptors capable of activating heterotrimeric guanine 
nucleotide-binding proteins, termed G-protein coupled receptors (GPCRs) (Krugmann et al., 
1999). The PI3K p110γ is thought to link GPCR signaling to PIP3 production, governing cell 
motility in inflammatory cells such as macrophages and to some extent in neutrophils (Hirsch et 
al., 2000).  
 
 
Fig. 2: Overview of PI3K isoforms.  
(Figure from Doepfner et al.; Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-
kinase / Akt Pathway and their Relevance to Drug Discovery Recent Patents on DNA & Gene Sequences 
2007, 1, 9-23 9) 
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The human class II of PI3Ks comprises the three isoforms PI3KC2α, PI3KC2β and PI3KC2γ 
(Katso et al., 2001). The hallmarks of class II family members are a substrate specificity 
restricted to PI and PI(4)P in vitro, and a C-terminal C2 domain. Although the precise cellular 
function of these enzymes remains generally unknown, recent reports have described class II 
PI3Ks as downstream transducers of activated polypeptide growth factor receptors (Arcaro et al., 
2000; Brown et al., 1999). The class III PI3K includes a homolog of the yeast vesicular protein-
sorting protein Vsp34 (Schu et al., 1993) and its major function is in intracellular trafficking 
events (Wurmser et al., 1999). 
 
2.2.2.1.  Inhibition of PI3K Signaling 
As the PI3Ks have been identified as playing critical roles in distinct cellular signaling processes, 
a precise understanding of these kinases, their substrates, products and effectors is of particular 
interest. Anomalies in signaling cascades have been described in various human diseases and the 
knowledge of their components is of high importance in the search for therapeutic, diagnostic and 
screening applications. A number of attempts have been made to better understand the PI3Ks in 
general, as well as to gain insight into the relevance and specificity of the different isoforms. The 
first selective pharmacological PI3K inhibitors to have been described are wortmannin (Arcaro & 
Wymann, 1993; Powis et al., 1994), a compound that was originally isolated from soil bacteria 
and is toxic to fungi, and LY294002 (Vlahos et al., 1994), a morpholino derivative of quercetin, a 
naturally occurring bioflavinoid and broad spectrum kinase inhibitor. Both compounds have been 
shown to inhibit cell growth at concentrations that would be expected to inhibit class I PI3Ks. 
However, as these pharmacological inhibitors display little selectivity within the family of the 
PI3Ks and might moreover affect other kinases, further research has been aimed at developing 
compounds with improved specificity and pharmacokinetic properties.  
 
2.2.2.2.  Gene-Targeting Strategies 
Gene-targeting strategies have been aimed at deleting specific PI3K isoforms and have uncovered 
key roles of the different enzymes in immunity, metabolism, cardiac function, cell proliferation 
and cancer susceptibility. Different knock-out mice have been generated with targeted deletions 
of genes encoding PI3K regulatory and catalytic subunits and have been phenotypically analysed 
(Vanhaesebroeck et al., 2005).  
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A knock-out mouse deleting the gene of the PI3K class IA catalytic subunit p110α has been 
generated by targeting the p85-binding domain of the PIK3CA gene, leading to the loss of 
expression of this specific isoform (Bi et al., 1999). The PIK3CAdel/del embryos showed a clear 
developmental delay and died between days 9.5 and 10.5 of embryonic development (Bi et al., 
1999). In embryos missing the p110α enzyme, a profound proliferation defect could be observed, 
which has further been supported by a failure in replication of p110α-deficient fibroblasts in 
culture medium, even when supplemented with growth factors. As the developmental period 
between E9.5 and E10.5 is known for increased cellular proliferation, growth, and differentiation, 
it has been hypothesized that the intrauterine death of  PIK3CAdel/del embryos at this stage is 
caused by the incapacity to provide the increased demand in proliferation signals maintained by 
PI3K signaling through the p110α isoform (Bi et al., 1999). Moreover, mice deficient in the 
p110α subunit displayed multiple vascular defects (Lelievre et al., 2005). A role in the control of 
cell growth by p110α was further highlighted by an increase in heart size in transgenic mice 
expressing constitutively active p110α and a decrease in heart size by expression of a dominant-
negative mutant form of this PI3K isoform in the heart (Shioi et al., 2000). The interpretation of 
knock-out data, however, has been complicated by the observation of an upregulation of other 
PI3K subunits after the deletion of one specific isoform. PIK3CAdel/del homozygous embryos 
apparently increased the expression of the PI3K class IA regulatory subunit p85/p55 raising the 
question of a contributing phenotypical effect by these adapter proteins. Further insight into the 
function of p110α has been given by the generation of mice carrying a knock-in mutation 
(D933A) that abrogates the p110α kinase activity (Foukas et al., 2006). Homozygocity for this 
mutation resulted in embryonic lethality while heterozygocity led to impaired signaling via the 
IRS proteins, key mediators of insulin, IGF-I and leptin action. As a result, the mutant mice 
displayed reduced somatic growth, hyperinsulinaemia, glucose intolerance, hyperphagia, and 
increased adiposity. Another study recently defined the p110α subunit as the critical lipid kinase 
required for insulin signaling in adipocytes and myotubes (Knight et al., 2006). The uncovering of 
p110α as a key intermediate in metabolic signaling raises concerns about potential mechanism-
based side-effects and the therapeutic use of PI3K inhibitors .     
The biological function of the PI3K class IA catalytic subunit p110β has been studied by a partial 
deletion allele knock-out mouse (Bi et al., 2002). Targeting of this specific isoform resulted in 
very early embryonic lethality at the homozygous state. Zygotes with the PIK3CBdel/del genotype 
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were nonviable very early after fertilization, leading to a deficiency of such embryos even at the 
blastocyst stage (Bi et al., 2002). Crossbreeding studies of p110β knock-out mice with p110α-
deleted mice did not reveal a possible redundant function of these two class IA catalytic subunits. 
However, a possible overlap in functions that might be manifested in subtle phenotypical 
abnormalities could not be ruled out so far (Bi et al., 2002).  
PI3K class IA catalytic subunit p110δ-deficient mice have been described by three different 
groups (Clayton et al., 2002; Jou et al., 2002; Okkenhaug et al., 2002). These studies revealed  a 
major function of p110δ primarily in B and T lymphocytes and a failure of the knock-out mice to 
mount normal immune responses.  The mice lacking p110δ showed a reduction in the amount of 
B1 and marginal zone B cells as well as lowered serum levels of immunoglobulins (Clayton et 
al., 2002). Furthermore, antigen receptor signaling in B and T cells was impaired and the mice 
were prone for the development of inflammatory bowel disease (Okkenhaug et al., 2002). 
However, despite the high level of p110δ expression in hematopoietic tissues, no significant 
differences have been found between wild-type and p110δ-deficient mice in the number or 
morphology of red blood cells and peripheral leukocytes, including neutrophils, eosinophils, 
basophils, monocytes, and lymphocytes, nor hemoglobin levels (Jou et al., 2002).  
Knock-out mice of the PI3K class IB catalytic subunit p110γ have been characterized by three 
different groups (Hirsch et al., 2000; Li et al., 2000; Sasaki et al., 2000b), describing phenotypes 
mainly affecting components of the innate immune response. Mice lacking p110γ showed an 
accumulation of defective neutrophils, exhibiting failure in their migratory capacity and reduced 
thymic cellularity. Moreover, chemoattractant-stimulated signal transduction was inhibited by 
impairment of PIP3 production in p110γ-deficient cells (Sasaki et al., 2000b). In contrast to 
p110δ, the deletion of p110γ resulted in no effect on B cells. Instead, this isoform appeared to 
regulate proliferation and cytokine production of T lymphocytes (Sasaki et al., 2000b). In view of 
the impaired migration capability of p110γ knock-out macrophages towards a wide range of 
chemotactic-stimuli, a crucial role for macrophage accumulation in the inflammatory response 
was furthermore suggested (Hirsch et al., 2000). Phenotypical analysis of mice expressing a 
kinase-dead p110γ only partially reproduced the phenotype of knock-out animals (Patrucco et al., 
2004). Whereas both mice exhibited an identical impairment in innate immune reactions, the 
p110γ-deficient mice additionally showed a basal enhancement of cardiac contractility and 
cardiac tissue damage upon pressure overload. It is therefore suggested that p110γ possesses a 
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kinase-independent activity controlling cardiac responses. A role of p110γ in the control of heart 
function has already been described by Crackower et al. (Crackower et al., 2002). These studies 
elucidated p110γ as a negative regulator of cardiac contractility through the inhibition of cAMP 
production.  
Regarding the regulatory PI3K subunits, gene-targeting strategies have been aimed at disrupting 
the adapter subunits p85α, its splice variants p55α and p50α, as well as p85β. Ablation of the 
whole gene PIK3R1, which encodes p85α and the mentioned splice variants, resulted in perinatal 
lethality (Fruman et al., 2000). However, disruption of the p85α gene only lead to an impaired B 
cell development, a reduction in the number of mature B cells, reduced B cell proliferative 
responses and no T cell-independent antibody production (Fruman et al., 1999). Homologous 
deletion of the adapter subunit p85β gene resulted in a growth reduction of the knock-out mice 
compared to their wild-type littermates (Ueki et al., 2002). Surprisingly, muscle and adipocyte 
tissues of both, the p85α and p85β knock-out mice exhibited increased insulin-stimulated PI3K 
pathway activation and enhanced translocation of the glucose transporter isoform-4 to the plasma 
membrane, as well as hypoglycemia with decreased plasma insulin (Fruman et al., 2000; Ueki et 
al., 2002). Moreover, the mice showed enlarged muscle fibres, brown fat necrosis and 
calcification of cardiac tissue (Fruman et al., 2000).    
       
2.2.2.3.  PI3K and Diseases 
As the PI3Ks are known to be involved in a wide spectrum of control mechanism within the cell, 
dysregulation of their function has been linked to various human diseases. Key roles of the PI3Ks 
have been described in the formation of tumors, metastasis, chronic inflammation, allergy and 
cardiovascular disease.      
The importance of PI3K signaling in human cancer is highlighted by the fact that there are 
numerous oncogenes and tumor suppressor genes whose dysregulation advantages PI3K 
signaling and promotes malignant properties of cells (Vivanco & Sawyers, 2002). A prominent 
finding in this context are mutations in the tumor suppressor gene phosphatase and tensin 
homolog (PTEN) that have been described in various human tumors (Aggerholm et al., 2000; Ali 
et al., 1999; Katso et al., 2001; Vivanco & Sawyers, 2002). PTEN is a phosphatase that 
antagonizes the action of PI3K by dephosphorylating the D-3 position of polyphosphoinositides 
(Maehama & Dixon, 1998). The DNA sequence copy number of PIK3CA, the gene encoding the 
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p110α catalytic subunit of the PI3K located on chromosome 3q26, is frequently increased in 
ovarian cancers (Shayesteh et al., 1999). Moreover, recent reports have described activating 
mutations in the PIK3CA gene in a variety of other human cancers, including, breast, colon and 
medulloblastoma (Kang et al., 2005; Samuels et al., 2004).  Although mutational alterations have 
predominantly been characterized for p110α so far, an increase in p110β activity has also been 
found in human colon cancer biopsies and adenocarcinoma cell lines (Benistant et al., 2000). 
Furthermore, a knock-down analysis of p110β in a prostate cancer mouse model suggested a 
requirement of this PI3K isoform for the formation of metastasis (Czauderna et al., 2003).  
Gene-targeting strategies have furthermore uncovered a role of p110γ in colorectal 
adenocarcinoma (Sasaki et al., 2000a). Lack of p110γ significantly increased the incidence rate 
for spontaneous development of multifocal carcinomas and invasive adenocarcinoma in the colon 
of mice. In humans, protein expression analysis of p110γ revealed a loss of this protein in a high 
number of colon cancer cell lines as well as in primary adenocarcinomas isolated from the colon 
of human patients (Sasaki et al., 2000a).  
As shown by different studies (Laffargue et al., 2002; Sasaki et al., 2000b), p110γ also plays a 
pivotal role in mediating leukocyte chemotaxis and activation, as well as mast cell degranulation, 
thus suggesting an involvement in inflammatory diseases. A specific contribution of the p110γ 
PI3K isoform to inflammation is supported by a recent study pointing out a protection of p110γ-
deficient mice from rheumatoid arthritis (RA) (Camps et al., 2005). The mice were largely 
protected against collagen II-specific antibody-induced arthritis, correlating with the defective 
neutrophil chemotaxis in this knock-out model (Camps et al., 2005). Moreover, treatment of 
different RA mouse models with orally active small-molecule inhibitors of p110γ suppressed the 
progression of the joint inflammation and damage in these mice (Camps et al., 2005). Other 
studies, however, have described a positive role of the PI3Ks in the inflammatory response. In 
RA, the anti-inflammatory cytokine IL-10 is spontaneously produced by macrophages and 
infiltrating blood lymphocytes in the rheumatic joint (Brennan & Foey, 2002). An involvement of 
PI3K signaling in the regulation of IL-10 is known (Crawley et al., 1996) and further analysis 
have demonstrated that the inhibition of PI3K signaling suppressed the production of this 
cytokine (Foey et al., 2002). 
The PI3K isoform p110δ has been shown to contribute to the inflammatory response as well 
(Clayton et al., 2002). Recent studies further supported this finding describing a contribution to 
Introduction  RTK Signaling in AML 
24 
allergen-IgE-induced mast cell activation and vascular permeability which is a common 
characteristics of chronic inflammations such as asthma (Lee et al., 2006a). Pharmalogical 
inhibition of p110δ resulted in a significant reduction of serum levels of IgE, attenuation of 
airway inflammation and hyperresponsiveness, by preventing vascular leakage in murine asthma 
models (Lee et al., 2006a; Lee et al., 2006b).    
Gene knock-out of the class IA regulatory subunits in skeletal muscles of mice resulted in a 
significant reduction in muscle weight and fiber size. Moreover, these mice exhibited muscle 
insulin resistance and whole-body glucose intolerance (Luo et al., 2006). The p85 regulatory 
subunits are therefore thought to act as critical mediators of PI3K signaling in the regulation of 
muscle growth and metabolism and furthermore, to make an important contribution to symptoms 
of hyperlipidemia associated with human type 2 diabetes (Luo et al., 2006). Diabetes is 
associated with vascular complications, including the impairment of vascular function and 
alterations in the reactivity of blood vessels to vasoactive agents (Jarrett, 1989). It has been 
shown that PI3K signaling plays a role in vascular growth, proliferation and apoptosis and is 
implicated in modulating vascular smooth muscle cell contractility (Zdychova & Komers, 2005). 
A recent study demonstrated that selective inhibition of PI3K attenuated the development of 
diabetes-induced abnormal vascular reactivity in the carotid arteries of diabetic rats (Yousif et al., 
2006).     
The growing understanding of the biological functions of PI3Ks opened insights into the 
interconnection of signaling events and cellular actions and made these kinases interesting targets 
in clinical and research areas. 
 
2.2.3.  Alteration of RTK Signaling in AML  
The increasing understanding of the pathogenesis of AML uncovered multiple genetic 
abnormalities necessary for the development of the disease. In the classical ‘two hit’ model, the 
second hit is thought to be caused by alterations in RTK signaling and various aberrantly 
regulated pathways have been described so far. Basically, there is an oncogenic potential in every 
receptor with tyrosine kinase activity. Structural modifications can lead to constitutive activation 
of RTKs, subversion of molecular control mechanisms and alterations in signal transduction. 
Deletions within the extracellular ligand binding domain alters ligand responsiveness, or 
eliminates negative control mechanisms that this structure might exert on the kinase domain. 
Even point mutations are able to induce overall ligand-independent conformational alterations 
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and hence activation of RTKs. Besides genetic alterations, over-expression of the wildtype 
receptor and/or autocrine receptor activation are known to play an important role in aberrant 
signal transduction.     
FLT3 is the most frequently mutated gene in AML. About one third of all patients show either 
internal tandem duplications (ITDs) within the juxtamembrane domain (Nakao et al., 1996) of 
FLT3, or mutations within the activation loop, predominantly at position D835 (Yamamoto et al., 
2001). FLT3 is a transmembrane receptor that has a crucial role in normal haematopoiesis. By 
signaling through the Ras/MAPK pathway the receptor exerts an important function in the control 
of cell proliferation. FLT3-ITD as well as activating loop mutations result in constitutive activation 
of the tyrosine kinase activity and of the whole signaling network (Gilliland & Griffin, 2002; 
Stirewalt & Radich, 2003).  
Activating point mutations in the kinase domain of the human colony-stimulating factor (M-CSF or 
CSF-I) receptor FMS occur in 5-20% of patients with AML (Ridge et al., 1990). FMS is a cell 
surface RTK and specific point mutations in this receptor have been implicated in neoplastic 
transformation by inducing ligand independence and constitutive activation of the tyrosine kinase 
activity. The mutation at codon 969 of FMS is thought to alter a negative regulatory site of the 
receptor and to up-regulate the response to ligand binding, conferring a growth advantage to the 
cell (Ridge et al., 1990). Co-expression of M-CSF together with FMS has been described for a 
small subset of AML patients, implicating autocrine stimulation of the wildtype receptor (Rambaldi 
et al., 1988). Moreover, patients with myeloplastic syndrome harboring FMS mutations were 
shown to have a significantly increased frequency of transformation to AML (Padua et al., 1998).   
Mutations in the RTK c-Kit have been preferentially associated with AML exhibiting either an 
inv(16) or a t(18;21) karyotype (Beghini et al., 2000). c-Kit encodes a transmembrane receptor that 
is activated SCF. Studies have shown that the levels of activation of c-Kit correlate with the rate of 
proliferation of myeloid leukemia cells and that receptor over-activation contributes to the 
excessive proliferation and aberrant differentiation of AML cells (Kuriu et al., 1991).     
Mutations in the RAS gene family have been described in about one fourth of AML cases, 
predominantly in N-Ras, but also in K-Ras and, although very rarely, in H-Ras (Bartram et al., 
1989; Farr et al., 1988). Primarily, mutations were found to affect the conversion of the active Ras-
GTP form to the inactive Ras-GDP form leading to constitutively activated Ras and enhanced 
downstream signaling. Besides, over-activation of downstream transducers have been described as 
a result of FLT-ITD affecting the autonomous growth of AML cells (Hayakawa et al., 2000). 
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Moreover, increased activation of the Ras/MAPK pathway has been shown to be caused by a 
commonly occurring chromosomal translocation. BCR-ABL is a chimeric oncoprotein that binds to 
Grb-2, the substrate protein known to link receptor tyrosine kinases to Ras signaling. Coupling of 
BCR-ABL-Grb-2 to SOS subsequently induces activation of the signaling pathway (Pendergast et 
al., 1993).        
FLT-ITD has furthermore been associated with increased activation of the Janus protein tyrosine 
kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. Constitutive 
tyrosine phosphorylation of the transcription factor STAT occurs in approximately 70% of AML 
cases, either through autophosphorylation of RTKs, or due to autocrine growth factor production 
(Birkenkamp et al., 2001). STAT signaling involves the control of diverse biological processes 
including cell proliferation, differentiation, development, and survival. Abnormal STAT signaling 
has been implicated in oncogenesis (Bromberg et al., 1999). Beside its role in FLT3 signaling, the 
JAK/STAT pathway has been associated with c-Kit-mediated ligand-independent survival and 
proliferation of AML cells. In fact, the c-Kit mutation Asp816 has been found to constitutively 
activate the JAK/STAT pathway (Ning et al., 2001). Moreover, chromosomal translocations 
resulting in the fusion of the JAK2 and the TEL gene have been described in human leukemias. The 
TEL-JAK2 fusion protein confers constitutive tyrosine kinase activity and cytokine-independent 
proliferation to hematopoietic cells (Lacronique et al., 1997; Peeters et al., 1997).  
An increasing body of evidence suggests a role of signaling by the IGF-IR through the 
PI3K/Akt/mTOR cascade in AML. IGF-I together with other cytokines have been described to be 
important for AML cell growth (Shimon & Shpilberg, 1995) and autocrine IGF-I production has 
been suggested to influence drug resistance in an AML cell line (Neri et al., 2003). Activation of 
the PI3K/Akt signaling pathway has furthermore been detected in blast cells from AML patients 
contributing to survival and proliferation of these cells (Grandage et al., 2005; Xu et al., 2003).  
      
2.2.4. Targeting RTK Signaling in AML 
Significant progress has been made over the past decades in the treatment of AML. Insights into the 
pathogenesis, detection of cytogenetic markers and classification of the disease have facilitated the 
definition of optimal therapy conditions. However, overall survival rates are still unsatisfactory and 
are highly influenced by complications resulting from therapy. Improvement of the current 
therapeutic approaches is thus urgently needed and major advances are hoped to arise from a more 
targeted therapy strategy. The increasing understanding of the high impact of receptor tyrosine 
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kinase signaling in AML and the discovery of specific alterations and dysregulation of signaling 
cascades sparked interest in specifically targeting RTK signaling in this disease. Besides, the 
growing number of molecularly targeted drugs displaying promising results in other human cancers 
further brought the focus onto targeting RTK signaling in AML and led to a plethora of preclinical 
and clinical trials.     
Given the fact that a large number of AML cases show constitutive activation of one or more 
RTKs, the use of small molecule inhibitors targeting their tyrosine kinase activity appears to 
represent a great promise. The remarkable activity of imatinib mesylate (Gleevec) targeting the 
BCR-ABL fusion protein in chronic myeloid leukemia (CML) (Druker, 2003) further developed 
the interest in the field of moleculary-targeted therapies in leukemia. The major focus in AML has 
been directed towards FLT3 and c-Kit. The uncovering of other receptors important for AML cell 
biology and the development of a plethora of new small molecule inhibitors, however, has 
broadened the field of targeted research in this malignancy.  
      
2.2.4.1. FLT3 
FLT3 is a class III receptor tyrosine kinase expressed by immature hematopoietic cells. Its 
expression is important for the normal development of stem cells and the immune system (Gilliland 
& Griffin, 2002).  The FLT3 ligand (FL) is a transmembrane protein that can be released as a 
soluble homodimeric protein. Both the membrane-bound, as well as the soluble form of FL are able 
to activate the tyrosine kinase activity of the receptor, and, synergistically with other hematopoietic 
growth factors, to induce proliferation of hematopoietic progenitor cells (Lyman & Williams, 
1995). Expression of FLT3 is found in the majority of AML patients and a crucial role of this 
receptor in the survival and proliferation of leukemic blasts has been described in various studies 
(Carow et al., 1996). Molecular alterations in the FLT3 receptor were first described in 1996 by 
Nakao et al (Nakao et al., 1996). Reverse transcriptase-polymerase chain reaction (RT-PCR) 
analysis revealed longer transcripts within the juxtamembrane domain of FLT3 in a large 
proportion of AML patients. This finding led to the discovery of commonly occurring ITDs within 
that region. A plethora of subsequent studies uncovered an overall frequency of FLT-ITDs of about 
one fourth of all cases of AML. More recently, in an additional cohort of AML patients, mutations 
within the activation loop of the kinase domain of FLT3 were found (Griffin, 2001; Yamamoto et 
al., 2001). Point mutations commonly occur at position 835 (Asp835) and have been reported in 
around 7% of AML cases so far. Taken together, the global incidence rate of altered FLT3 function 
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in AML patients caused either by FLT3-ITD, or by FLT3 activation loop mutation, represents 
almost one third of all cases. The high prevalence of activating mutations in this receptor therefore 
makes FLT3 one of the most interesting targets for molecularly based therapies. 
Indoline tyrosine kinase inhibitors are known to inhibit the tyrosine kinase activity of a number of 
RTKs, such as FLT3, c-Kit, PDGFR, VEGFR or the FGFR. Pre-clinical studies have examined the 
effect on the FLT3 receptor and its signaling and initial clinical trials have been aimed at evaluating 
their biological activity in AML patients (Fiedler et al., 2003; Fiedler et al., 2005; Giles et al., 2003; 
Mesters et al., 2001; O'Farrell et al., 2003b; O'Farrell et al., 2004; Smolich et al., 2001; Yee et al., 
2002). SU5416 and the related compound SU5614 were shown to inhibit the kinase activity of both 
the wildtype FLT3, as well as the mutated receptor. Furthermore, both compounds inhibited 
downstream signaling via the MAPK and the STAT pathway, markedly decreased cellular 
proliferation and increased apoptosis in AML (Smolich et al., 2001; Yee et al., 2002). In phase II 
clinical studies evaluating SU5416 in elderly AML patients, or patients with relapsed and/or 
refractory disease, single agent treatment had only minimal clinical activity. Partial remission and 
hematopoietic improvement was seen, however, in a small cohort of patients and these 
improvements were of short duration (Fiedler et al., 2003; Giles et al., 2003; O'Farrell et al., 2004). 
A significant decrease in blast cell count down to undetectable levels and stable remission after 
administration of SU5416 has only been described in a single case study of a patient with relapsed 
AML (Mesters et al., 2001). SU11248 is another oral multitargeted kinase inhibitor that targets 
FLT3 together with other RTKs. Pre-clinical studies showed in vitro activity against the wildtype, 
as well as the mutated FLT3 receptor and in vivo activity against xenograft FLT3-ITD AML tumors 
in engraftment mouse models  (O'Farrell et al., 2003a). Phase I clinical trials underlined the action 
of SU11248 against the FLT3 kinase activity. Monotherapy of SU11248, however, only induced 
partial remission in a small number of AML patients for a short duration (Fiedler et al., 2005; 
O'Farrell et al., 2003b).  
PKC412 is small molecule FLT3 inhibitor that was identified and characterized by Weisberg et al. 
(Weisberg et al., 2002). PKC412 selectively induces G1 cell cycle arrest and apoptosis in cell lines 
expressing mutant FLT3 by directly inhibiting its kinase activity. Progression of leukemia was 
inhibited in FLT3-ITD transduced mouse models making this inhibitor a valuable candidate for 
clinical trials in patients carrying mutant FLT3 receptors (Weisberg et al., 2002). Subsequent pre-
clinical studies highlighted the potential use of this inhibitor against FLT3 kinase activity and 
reported an effect of PKC412 on the phosphorylation of the downstream targets Akt, Erk and 
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STAT5 (George et al., 2004). A phase II clinical trial in a small cohort of patients showed 
significant clinical benefit and a 50% decrease in peripheral blast counts in most patients with 
mutated FLT3, in line with inhibition of receptor autophosphorylation (Stone et al., 2005). 
Levis et al. characterized CEP-701, an indolocarbazole derivative with potent activity against 
autophosphorylation of wild-type and constitutively activated FLT3 (Levis et al., 2002). CEP-701 
inhibited the FLT3 downstream targets Erk and STAT5 and induced a cytotoxic effect in AML 
patient cells harboring FLT3-ITDs. Furthermore, CEP-701 prolonged survival in a mouse model of 
FLT3-ITD leukemia (Levis et al., 2002). A recent study substantiated the potential of CEP-701 in 
reducing cell viability and FLT3 phosphorylation in a large number of patient cells (Knapper et al., 
2006b). In vivo hematological activity of CEP-701 has been studied in clinical phase I/II trials. 
Treatment of patients with refractory, relapsed, or poor  prognosis AML expressing FLT3-
activating mutations with CEP-701 revealed biological activity and a measurable clinical response 
including reduction in peripheral and bone marrow blood blasts in some patients (Smith et al., 
2004). The clinical response was more pronounced in patients with mutated FLT3 than in those 
expressing the wild-type receptor (Knapper et al., 2006a). 
Recently, tandutinib (MLN518) was identified as a novel, relatively specific FLT3 antagonist 
(Deangelo et al., 2006). Pre-clinical studies showed activity against FLT-ITD autophosphorylation 
and inhibition of AML cell proliferation  in vitro (Kelly et al., 2002). A clinical phase II study 
reported evidence of antileukemic activity with a decrease in both peripheral and bone marrow 
blast count in a small cohort of patients treated with tandutinib (Deangelo et al., 2006).  
 
2.2.4.2. c-Kit 
c-Kit encodes another transmembrane protein with tyrosine kinase activity and is a proto-oncogene 
thought to play an important role in normal hematopoiesis. c-Kit expression has been detected in a 
large number of hematopoietic cell lines, in primary blasts of human AML patients, but to a much 
lower level in normal bone marrow cells (Wang et al., 1989). Tyrosine phosphorylation and 
activation of c-Kit is induced by binding of SCF and results in proliferation of human leukemia 
blast cells in a substantial fraction of AML cases. The constitutive, ligand-independent activation of 
c-Kit found in leukemic cells suggests that this receptor is involved in the excessive proliferation 
and aberrant differentiation of these cancer cells (Kanakura et al., 1993). Moreover, a direct 
correlation has been found between the levels of c-Kit tyrosine phosphorylation and the 
proliferation rate in AML cell lines (Kuriu et al., 1991). Mutations in c-Kit are thought to be 
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exclusively associated with core binding factor leukemias (CBF-AML). In addition to mutations 
within the tyrosine kinase domain of c-Kit at position 816, insertions and deletions have been 
described (Care et al., 2003; Gari et al., 1999).  
Imatinib, also known as STI571 or Gleevec, has been shown to be a very promising small molecule 
inhibitor targeting the tyrosine kinase activity of the BCR-ABL fusion protein commonly found in 
CML. Moreover, the inhibitor was shown to effectively inhibit the PDGFR as well as c-Kit 
(Heinrich et al., 2000). Imatinib prevented autophosphorylation of c-Kit and activation of the 
downstream signal transducers MAPK and Akt. Furthermore, treatment of an AML cell line 
expressing the BCR-ABL fusion protein induced apoptosis and significantly increased the 
sensitivity to chemotherapeutical agents (Fang et al., 2000). In c-Kit-positive primary AML patient 
blasts, however, Imatinib exerted only marginal effects on cell growth (Scappini et al., 2001). 
Nevertheless, a pre-clinical study analyzing cells expressing c-Kit mutants cloned from AML 
patients reported a dose-dependent increase in apoptosis upon treatment with the inhibitor 
(Cammenga et al., 2005). In a first clinical phase II trial of patients with refractory or recurrent 
AML, Imatinib as single agent did not induce any significant beneficial responses (Cortes et al., 
2003). A later phase II pilot study including a small cohort of c-Kit-positive patients, however, 
showed high efficacy of Imatinib resulting in the inhibition of c-Kit tyrosine phosphorylation and 
promising results in a subset of patients meeting the criteria for complete hematological remission 
(Kindler et al., 2004). Consistently, different case studies have described a potential benefit of 
Imatinib treatment for c-Kit-positive AML patients and carriers of specific c-Kit mutations (Cairoli 
et al., 2005; Ito et al., 2005; Jentsch-Ullrich et al., 2004; Kindler et al., 2003; Pompetti et al., 2006; 
Schittenhelm et al., 2003; Viniou et al., 2004; Yamaguchi & Konishi, 2003). 
 
2.2.4.3. IGF-IR 
The IGF-IR is a transmembrane tyrosine kinase widely expressed in many human tissues and cell 
types, with high homology to the IR. Activation of the receptor is achieved by binding of the IGFs 
to the extracellular domain, triggering autophosphorylation of three tyrosine residues within the 
kinase domain (Kato et al., 1993). In AML, signaling by the IGF-IR has not yet been extensively 
studied, however, expression of the IGF-IR was reported in human AML cells (Hizuka et al., 1987; 
Sukegawa et al., 1987). While mutations resulting in constitutive tyrosine kinase activity of the 
IGF-IR have not been described to date, over-expression of the receptor and/or the establishment of 
autocrine loops involving the ligands IGF-I and IGF-II have been reported in various human 
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cancers (Khandwala et al., 2000). The importance of IGF-I as a growth factor in combination with 
other cytokines has been described in human AML cells (Shimon & Shpilberg, 1995). A recent 
study further underlined the importance of IGF-IR signaling by showing an association between 
increased expression of IGF-I and resistance to the chemotherapeutical agent Cytarabine (Ara-C) in 
leukemia (Abe et al., 2006). Gene expression profiling of Ara-C-resistant human myeloid leukemia 
cells revealed an up-regulation of IGF-I. Subsequent analysis of AML cases uncovered higher IGF-
I expression in patients with refractory disease after Ara-C therapy compared to patient cells 
analyzed at diagnosis (Abe et al., 2006). Consistently, a role of autocrine IGF-I production in drug 
resistance was previously suggested in an AML cell line (Neri et al., 2003). In addition, IGF-I 
signaling is known to play a crucial function in other hematological malignancies such as multiple 
myeloma (MM) (Yasui et al., 2006), and several anti-IGF-IR experimental therapies have been 
shown to inhibit multiple myeloma proliferation in vitro and in vivo (Mitsiades et al., 2004). 
Blocking the IGF-IR in the Ara-C resistant myeloid cell line described above inhibited cell growth 
and led to the induction of apoptosis, suggesting that the IGF-IR and its downstream signaling 
pathways may provide valuable novel targets to overcome Ara-C resistance in AML (Abe et al., 
2006).  
The increasing understanding of the importance of the IGF-IR signaling pathway in AML cell 
proliferation, viability and drug-resistance makes this system an interesting new molecular target 
for cancer therapy. Promising small molecule inhibitor have been generated and a wide variety of 
strategies are now available to target IGF signaling (Guerreiro et al., 2006). 
 
2.2.5.  Downstream Signal Transducers 
Targeting pathways downstream of RTKs is another approach to down-regulate an overactivated 
signaling system with significant therapeutic advantages. The growing understanding of the 
complexity of RTK signaling networks has indeed revealed a number of promising target proteins 
contributing to altered signaling in cancer cells. As described above, deregulation of RTKs 
frequently induces over-activation of the PI3K/Akt, Ras/MAPK and JAK/STAT cascades in AML. 
Inhibitors targeting various signal transducer proteins including Akt and mTOR, Ras and MEK 
have been developed and are being tested in preclinical studies in various human cancers including 
AML.  
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2.2.5.1. PI3K/AKT 
The PI3K pathway is essential for different physiological processes including transcription, 
translation, cell cycle progression and apoptosis. The PI3K cascade is the signaling system most 
frequently targeted by genetic alterations in human cancer, along with p53 and the retinoblastoma 
pathway. Genomic aberrations such as amplifications, rearrangements and mutations induce 
activation of the pathway, thus providing the tumor cells with a strong growth advantage (Osaki et 
al., 2004). The PI3Ks are a family of eight enzymes in humans, which are subdivided into 3 classes 
(I-III), based on sequence homology and substrate specificity (Vanhaesebroeck et al., 1997a). Class 
IA and class II PI3Ks transduce signals from activated RTKs. These PI3Ks are also activated by 
oncogenic mutants of Ras, such as N- and K-Ras, which are found in AML. Several downstream 
targets of PI3K transduce their proliferative and anti-apoptotic signals, including Akt/PKB, PDK-1, 
FKHR, GSK-3β, TSC1 and TSC2, BAD, Rheb, mTOR, S6K, 4E-BP. The importance of the 
PI3K/Akt axis in AML cell progression has been highlighted by several studies (Kubota et al., 
2004; Min et al., 2003; Xu et al., 2003; Zhao et al., 2004). Constitutive activation of PI3K was 
found in more than 50% of AML cases and the activation of Akt was significantly higher in 
spontaneously proliferating AML cells than in cells that did not proliferate spontaneously (Kubota 
et al., 2004). Moreover, constitutive phosphorylation of Akt at Ser473 negatively correlated with 
the overall survival rate of AML patients (Min et al., 2003).  
The inhibition of PI3Ks by the generic inhibitor LY294002 resulted in reduced Akt kinase activity, 
dephosphorylation of Akt and BAD and an increase in apoptosis in AML cell lines (Xu et al., 2003; 
Zhao et al., 2004). PI3K inhibition in primary AML blasts resulted in significantly reduced 
clonogenic growth (Zhao et al., 2004). Moreover, inhibition of the pathway sensitized AML cells to 
chemotherapy-induced apoptosis (O'Gorman et al., 2000). A recent study examined the anti-
leukemic effect of the novel small-molecule multiple kinase inhibitor KP372-1 in AML (Zeng et 
al., 2006). KP372-1 potently inhibited the kinase activity of Akt, PDK1and FLT3 in a dose-
dependent manner. The inhibitor induced pronounced apoptosis in AML cell lines and primary 
blasts. Furthermore, KP372-1 decreased the colony-forming ability of primary AML blasts with 
minimal cytotoxic effects on normal progenitor cells (Zeng et al., 2006). The finding that normal 
hematopoietic progenitor cells were less affected by inhibitors targeting PI3K signaling than AML 
cells was previously described by others (Xu et al., 2003; Zhao et al., 2004) and further supports the 
feasibility of targeting this fundamental signal transduction network for AML therapy. The use of 
generic non-selective inhibitors such as LY294002 or wortmannin, however, has been shown to 
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cause severe side effects in xenograft models (Cheong et al., 2003) and the identification of more 
selective inhibitors is required. Recently, IC78114, a class IA PI3K p110δ-selective inhibitor, was 
shown to efficiently suppress constitutive as well as FLT3-stimulated activation of Akt in AML 
blasts to the same extent as the non-selective generic PI3K inhibitor LY294002 (Sujobert et al., 
2005). Moreover, the isoform-selective inhibitor suppressed AML cell proliferation without 
affecting the proliferation of normal progenitor cells.          
         
2.2.5.2.  mTOR 
mTOR is a key regulator of growth and survival and is activated by various RTK receptors. Once 
activated, the serine/threonine kinase phosphorylates its downstream targets, the ribosomal S6K 
and 4E-BP. Aberrant activation of the mTOR signaling pathway in AML cells is supported by the 
finding of constitutive phosphorylation of S6K and 4E-BP in the majority of AML samples (Recher 
et al., 2005).  
Rapamycin is a well known inhibitor of mTOR and is used clinically as an immunosuppressant and 
antiproliferative agent (Hidalgo & Rowinsky, 2000; Schreiber, 1991). Studies evaluating the effect 
of rapamycin in AML cells have reported marked activity of the inhibitor in down-regulating 
phosphorylation of S6K and 4E-BP (Hahn et al., 2005; Mohi et al., 2004; Recher et al., 2005) and 
inhibiting cell growth by blocking the cell cycle, particularly in very immature AML cell lines 
(Recher et al., 2005). Treatment of primary AML blasts with the mTOR inhibitor impaired their 
clonogenic properties, while normal hematopoietic progenitors were not affected. Moreover, 
rapamycin synergistically induced apoptosis in conjunction with protein kinase inhibitors (Hahn et 
al., 2005; Mohi et al., 2004). A pilot clinical study comprising a small number of patients with 
refractory, relapsed or poor prognosis AML showed significant responses suggesting that 
rapamycin could be of clinical interest for AML treatment. Partial remission or stabilization of the 
disease was reported in five out of nine patients analyzed (Recher et al., 2005). Evaluation of 
RAD001 (Everolimus), a rapamycin derivative, revealed only marginal effects on AML cell growth 
as a single-agent. Combined treatment together with the chemotherapeutical agent Ara-C, however, 
significantly enhanced the response of AML cells to the cytotoxic drug (Xu et al., 2003).  
 
2.2.5.3.  RAS/RAF/MEK/ERK 
The MAPK signaling cascade is yet another important system that integrates extracellular stimuli 
and transduces them to cellular responses, such as proliferation, differentiation and survival. RTKs 
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signal through activation of the small GTP-binding protein Ras via the adapter molecule Grb2 and 
the guanine nucleotide exchange factor son of sevenless (SOS). Sequential stimulation of the 
cytoplasmatic proteins Raf, MEK and Erk, collectively known as MAPKs, finally results in the 
regulation of gene transcription by ELK1 and the STAT proteins (Seger & Krebs, 1995). The 
MAPK pathway was shown to be constitutively activated in a large number of AML cells, 
suggesting a pivotal role for this cascade in leukemogenesis (Kim et al., 1999; Towatari et al., 
1997). N-Ras, but also K-Ras or H-Ras, are frequently mutated in AML cells causing dysregulation 
and activation of the signaling system (Bartram et al., 1989; Farr et al., 1988). As described above, 
altered signaling emanating from FLT3 receptors containing ITDs also relies, at least in part, on 
activation of MAPKs, thereby inducing autonomous growth of myeloid cell lines and primary 
AML blasts (Hayakawa et al., 2000). Moreover, the BCR-ABL chimeric oncoprotein that results 
from chromosomal translocation is yet another trigger for alterations in the MAPK pathway 
(Pendergast et al., 1993).  
PD98059 and PD184352 are small molecule inhibitors that strongly reduce MAPK activity and 
profoundly impair growth and survival of AML cells (Milella et al., 2002). The primary effect of 
the inhibitors included cell cycle arrest followed by apoptosis in a significant percentage of 
leukemic blasts (Lunghi et al., 2003). The inhibitors abrogated the clonogenic properties of primary 
AML cells, but had only minimal effects on normal hematopoietic progenitors. Moreover, 
impairment of MAPK signaling sensitized leukemic cells to spontaneous, as well as drug-induced 
apoptosis (Milella et al., 2002; Wu et al., 2004). U0126, another potent MEK inhibitor, led to a 
highly significant induction of apoptosis in some AML cell lines and blasts, while no apparent 
responses were seen in others (James et al., 2003). Interestingly, a particularly pronounced effect on 
the most primitive types of leukemia, which are often found to be the most resistant to standard 
chemotherapy, was observed. A possible synergistic effect in combination with the 
chemotherapeutical agent Ara-C was also observed. Moreover, control cells were completely 
insensitive to the inhibitor (James et al., 2003). A phase I clinical trial addressed the question of 
efficacy of Sorafenib (BAY43-9006), a Raf-1 kinase inhibitor, in AML patients (Tong et al., 2006). 
Although no significant inhibition of the MAPK cascade, as assessed by phosphorylation of Erk, 
could be detected, c-Kit-mediated pathway activation was largely abolished upon treatment with 
the inhibitor. In fact, further analysis revealed an almost complete inhibition of c-Kit activity at 
high doses of the inhibitor, putting c-Kit forward as another target of Sorafenib (Tong et al., 2006). 
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Another approach to target the MAPK pathway is based on interfering with Ras protein function. 
Proper membrane localization of Ras proteins is a critical step for successful signal transduction. 
Binding of Ras to the plasma membrane, which is required for its full biological activity, is 
accomplished by diverse post-translational modifications of the protein, which are catalyzed by 
specific enzymes. Various inhibitors against these enzymes have been generated in order to impair 
the post-translational modification steps. The most significant progress has been made in the 
identification and characterization of farnesyltransferase inhibitors (FTIs). Treatment of tumor cells 
with these inhibitors results in various effects including alteration of cell cycle progression, 
induction of apoptosis, changes in cell morphology and inhibition of anchorage-independent 
growth (Sebti & Hamilton, 2000). Several FTIs have entered clinical trials for AML with promising 
results. Zarnestra (R115777) significantly inhibited the colony growth of human AML blasts and 
induced apoptosis. In combination with other drugs the effect of the FTI was even more 
pronounced (Korycka et al., 2004). Phase I and II clinical trials have described a promising 
biological activity of Zarnestra, inducing antileukemic responses in a subgroup of patients treated 
with the inhibitor (Karp et al., 2001; Lancet et al., 2006). Accordingly, evaluation of the FTI BMS-
214662 showed strong evidence of antileukemic activity and a good tolerability of the compound in 
a cohort of patients with relapsed or refractory disease (Cortes et al., 2005). 
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3. RESULTS 
 
3.1. Aims 
 
 
Part I – Autocrine insulin-like growth factor-I signaling promotes growth and survival of  
human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway 
 
RTKs and signaling cascades such as the PI3K/Akt pathway have been shown to play a crucial 
role in various human cancers. Promising new cancer therapies focus on pharmacological 
inhibitors selectively targeting signaling molecules of those survival pathways. Therefore, the 
role of RTK signaling and its biological function was investigated in AML. A panel of AML cell 
lines and patient blast cells were analyzed for the expression of various signaling proteins and 
their role in cellular responses. The main focus was laid on the IGF-I signaling network as high 
expression levels of the IGF-IR, the IR, as well as autocrine production of IGF-I were detected in 
the cells studied. Various apporaches were aimed at investigating the potential of targeting this 
signaling system including RNAi, neutralizing antibodies as well as the use of the novel IGF-IR 
kinase inhibitor NVP-AEW541 (Novartis) as an antitumor agent in AML. Besides, the 
involvement of downstream transducers of the IGF-IR on AML cell growth and survival was 
evaluated. Class IA PI3K isoforms were specifically targeted in order to better understand their 
role in cellular responses and to investigate their potential as molecular targets for cancer 
treatment.  
Together, we could describe a novel role for autocrine IGF-I signaling in the growth and survival 
of AML cells. The inhibition of the IGF-IR/PI3K signaling network in combination with 
chemotherapeutic agents may represent a novel approach to target human AML. 
 
 
Part II – Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain 
tumours and neuroendocrine tumours 
 
Eight mammalian PI3K isoforms exist which are subdivided into three classes. While much 
attention has been given to the class I isoforms, little is known about the role of class II PI3Ks in 
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human cancer. Therefore, the expression pattern and functions of the class II PI3K isoform 
????????????? investigated in tumor samples and cell lines from AML, glioblastoma multiforme 
(GBM), medulloblastoma (MB), neuroblastoma (NB), and small cell lung cancer (SCLC). 
Furthermore, the use of two novel isoform-specific pharmacological inhibitors (PI701, PI702) 
and RNAi to inhibit PI3KC2β was evaluated. The effect on signal transduction, cell growth and 
survival and the potential of PI3KC2β as a novel drug target in AML, brain tumors and 
neuroendocrine tumors was analyzed.  
In summary, we could show that PI3KC2β contributes to proliferation and survival of AML, 
brain tumors and neuroendocrine tumors and plays an important role in the migratory capacity of 
highly motile breast cancer cells. Moreover, inhibition of this class II PI3K isoform sensitized 
AML and glioblastoma cells to chemotherapeutic agent.    
 
 
Part III – Investigation of the molecular determinants of rapamycin sensitivity in acute 
myeloid leukemia cells 
 
Protein expression analysis in a panel of AML cells revealed significant differences in the 
expression levels of mTOR. Therefore, the role of mTOR in AML cell growth and survival was 
investigated and cellular responses to the mTOR inhibitor rapamycin were compared in cells 
expressing high levels of mTOR (mTORhigh) and cells expressing low levels of mTOR 
(mTORlow). Moreover, an RNAi screen was aimed at uncovering kinases which modulate the 
sensitivity to rapamycin. Screening a kinome siRNA library identified human kinases which 
strongly enhanced the anti-proliferative effect of rapamycin in AML cells and played a role in 
tumor cell survival. The use of specific inhibitors or shRNA targeting those kinases was further 
aimed at investigating their potential as molecular targets for AML treatment in combination with 
rapamycin. 
Together, our data show an important role of mTOR for cancer cell proliferation and survival in a 
subclass of human AML cells. Preliminary results suggest that targeting certain RTKs (IGF-IR, 
FLT3, FGFR1) or signal transducers (SYK, ZAP70) in combination with rapamycin bears great 
potential for AML therapy.  
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Part IV – Novel role for insulin as an autocrine growth factor for malignant brain tumour 
cells 
 
Atypical teratoid/rhabdoid tumors (AT/RTs) of the central nervous system (CNS) are childhood 
malignancies associated with poor prognosis. To gain better insight into the molecular 
background of this disease, the role of RTKs and their involvement in tumor gowth and survival 
was investigated in a panel of AT/RT and malignant rhabdoid tumor (MRT) cell lines. Over-
expression of the IR and IGF-IR was detected in the cancer cells when compared to control 
normal brain tissue and insulin was shown to be secreted by AT/RT cells. Therefore, the potential 
of targeting the IR or IGF-IR signaling system in human AT/RT and MRT cell lines was 
investigated by the use of RNAi, neutralizing antibodies or NVP-AEW541. Several signaling 
proteins such as the receptors (IR and IGF-IR) as well as downstream transducers such as the 
class I PI3K isoform p110α were analyzed for their impact in tumor growth and survival and 
their potential as anti-proliferative target.  
In short, a novel role for autocrine signaling by insulin and the IR in growth and survival of 
malignant human CNS tumor cells could be described.  
 
 
Part V – Targeting the phosphoinositide 3-kinase isoform p110δ impairs growth and 
survival in neuroblastoma cells 
 
Neuroblastoma (NB) is the most common extra cranial solid tumor occurring in children. 
Treatment outcome is still unsatisfying and a better understanding of the biology of this cancer is 
aimed at the identification of novel therapeutic targets in this cancer. A promising field of 
investigation is to target RTKs and their downstream mediators. Therefore, the role of RTK/PI3K 
signaling and the potential of targeting specific class I PI3K isoforms as a novel anti-proliferative 
approach was investigated in NB cells. Expression levels of PI3Ks was evaluated in primary 
human neuroblastoma samples and cell lines and the effects on cell survival and signal 
transduction was analyzed following isoform-specific down-regulation of p110α or p110δ in SH-
SY5Y and LA-N-1 cells. 
In conclusion, a novel function of the class IA PI3K isoform p110δ in neuroblastoma growth and 
survival was uncovered. 
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3.2. Autocrine insulin-like growth factor-I signaling promotes growth and survival of 
human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway 
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Supplementary Figure 1 (a) Expression of IGF-IRβ and IR in 20 human AML patient blast cells and 
normal bone marrow cells (N). (b) PI3K class IA regulatory subunit p85α, catalytic subunits p110α, 
p110β, p110δ and the PI3K antagonist phosphatase and tensin homolog (PTEN). (c) Pathway activation 
monitored by the phosphorylation status of protein kinase B (PKB/Akt: Thr308) and extracellular signal-
regulated kinase (Erk: Thr202/Tyr204). Actin was used as a loading control. 
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3.3. Targeting PI3KC2β impairs proliferation and survival in acute leukemia, brain 
tumours and neuroendocrine tumours  
(British Journal of Cancer; Manuscript submitted) 
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3.4. Investigation of the Molecular Determinants of Rapamycin Sensitivity in Acute 
Myeloid Leukemia Cells  
(Manuscript in preparation) 
 
 
Results  Rapamycin Sensitivity in AML 
 82 
 
Results  Rapamycin Sensitivity in AML 
 83 
 
Results  Rapamycin Sensitivity in AML 
 84 
 
Results  Rapamycin Sensitivity in AML 
 85 
 
Results  Rapamycin Sensitivity in AML 
 86 
Results  Rapamycin Sensitivity in AML 
 87 
 
Results  Rapamycin Sensitivity in AML 
 88 
 
 
 
 
  
 
 
Results  Rapamycin Sensitivity in AML 
 89 
 
Results  Rapamycin Sensitivity in AML 
 90 
Results  Rapamycin Sensitivity in AML 
 91 
 
Results  Rapamycin Sensitivity in AML 
 92 
 
Results  Rapamycin Sensitivity in AML 
 93 
 
Results  Rapamycin Sensitivity in AML 
 94 
 
Results  Rapamycin Sensitivity in AML 
 95 
 
Results  Rapamycin Sensitivity in AML 
 96 
Results  Rapamycin Sensitivity in AML 
 97 
 
Results  Rapamycin Sensitivity in AML 
 98 
 
Results  Rapamycin Sensitivity in AML 
 99 
 
Results  Rapamycin Sensitivity in AML 
 100 
 
Results  Rapamycin Sensitivity in AML 
 101 
 
Results  Rapamycin Sensitivity in AML 
 102 
 
Results  Rapamycin Sensitivity in AML 
 103 
 
Results  Rapamycin Sensitivity in AML 
 104 
Results  Autocrine Insulin Signalling in CNS Tumours 
105 
3.5. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells 
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3.6. Targeting the phosphoinositide 3-kinase isoform p110? impairs growth and survival 
in neuroblastoma cells  
 (Clinical Cancer Research; Manuscript in press) 
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4. CONCLUSIONS AND PERSPECTIVES 
 
A better understanding of the mechanisms underlying tumor formation has resulted in a new era 
of cancer treatment strategies using highly-specific inhibitors for gene targeted therapies. 
Extensive research aimed at identifying promising new molecular targets has placed RTK 
signaling into the front ranks. Several studies have proven a high efficacy of targeting the RTK 
system in cancer treatment and the use of novel small-molecule inhibitors lead to promising 
results and greatly reduced incidence rates of adverse side effects. Moreover, a trend towards 
combinatorial therapies, in which multiple signaling pathways are being targeted at the same 
time, is arising. Over the last years, great progress has been made in understanding the 
pathogenesis of AML revealing a number of promising targets, such as FLT3 and c-Kit. Despite 
the fact that clinical trials have corroborated the feasibility of using these newly developed agents 
in AML and have demonstrated acceptable tolerabilities in patients, they are not yet used as a 
standard treatment. Moreover, due to the heterogeneity of the disease, the inhibitors currently in 
clinical trials have only shown satisfactory results in certain subgroups of patients. Therefore, a 
number of other molecular targets remain yet to be discovered and this study was aimed at 
extending the current understanding of RTK signaling in human cancers, AML in particular, and 
the field of novel useful approaches.   
 
The studies presented in this thesis on the IGF-IR/PI3K signaling system in AML blasts and cell 
lines highlighted the significant contribution of this network to cancer cell survival. We could 
show that IGF-I promotes growth and survival of AML blasts and that it activates intracellular 
signaling mediators including Akt and ERK. Furthermore, high expression levels of the IGF-IR 
were found in a panel of primary AML blasts and cell lines. Besides, we discovered that IGF-I 
was consistently secreted by the AML cells implying the presence of an autocrine signaling loop 
involving IGF-I and the IGF-IR. Previous studies had already described expression of the IGF-IR 
in human leukemias and over-expression of the IGF-IR was stated to harbinger transformation 
from MDS to AML as the IGF-IR appeared to have higher to lower expression rate in turn from 
AML to MDS to normal controls (Qi et al., 2006; Zumkeller & Burdach, 1999). Moreover, the 
expression of the IGF-IR negatively correlated with apoptosis suggesting a protective role for this 
receptor (Qi et al., 2006). Our finding of an autocrine IGF-I production and the involvement of 
the IGF-I/IGF-IR signaling system in AML cell growth and proliferation could be a more 
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relevant explanation for that survival advantage. Indeed we could show that blockage of the IGF-
IR by different approaches suppressed AML cell growth at least in part by the induction of 
apoptosis.  
In another study comparing the expression profiles of drug-resistant AML cells to drug-sensitive 
cells, an up-regulation of IGF-I could be associated with the resistance to the chemotherapeutical 
agent Ara-C (Abe et al., 2006). Consistently, IGF-I expression levels were found to be higher in 
patients at the refractory stage who received an Ara-C combined therapy, than in patients at 
diagnosis (Abe et al., 2006). It is a common finding that prolonged drug treatment can induce 
therapy resistance and that selected malignant cells can bypass the treatment efficacy by the 
activation of parallel signaling pathway. Indeed, sustained exposure of AML cells to tyrosine 
kinase inhibitors targeting FLT3 was shown to result in the activation of N-Ras and its signaling 
pathway (Piloto et al., 2007). Recently, another study described increased activation of the 
PI3K/Akt system upon treatment of AML patient blasts with the rapamycin derivative inhibitor 
everolimus (RAD001). Interestingly, the effect was explained by an IGF-I/IGF-IR autocrine 
signaling loop (Tamburini et al., 2007).  
It is beyond question that we are still not familiar with all the sophisticated characteristics and 
reactions of cancer cells. However, current approaches targeting multiple signaling pathways 
definitively bear great potential in regard to treatment efficacy. In this notion, it was also our 
interest to investigate the potential of combining different targeting strategies. We could show 
that the use of NVP-AEW541 to block the IGF-IR kinase activity sensitized AML cells to 
chemotherapeutical agents and increased apoptosis. Besides, targeting the system further 
downstream by down-regulating or inhibiting the PI3K isoforms p110β or p110δ enhanced the 
action of etoposide or Ara-C. An important role of p110δ in AML cell proliferation was already 
described before (Billottet et al., 2006; Sujobert et al., 2005). However, we could show for the 
first time that the class I PI3K p110β was also widely expressed in the panel of AML cells 
analyzed and essentially contributed to cell growth.  
 
While much attention has been paid to the understanding of the PI3K class I isoforms, little is 
known on the role of the other classes in regard to human cancer. Given the fact that also the 
class II isoforms were shown to integrate signals from growth factor receptors and to contribute 
to the generation of 3’-phosphoinositides, a potential role in cancer formation is certainly given 
(Arcaro et al., 2000). Indeed, recent studies have elucidated the role of PI3KC2β in cytoskeletal 
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organization, cell migration and survival of human tumor cells (Katso et al., 2006; Maffucci et 
al., 2005). In this context, we conducted an extensive analysis of PI3KC2β in a number of human 
tumors. We could show that PI3KC2β was widely expressed in a panel of AML, glioblastoma 
multiforme, medulloblastoma, neuroblastoma, and small cell lung cancer cells. Over-expression 
of the mRNA as well as the protein was visible in certain subgroups, going in hand with previous 
studies that showed up-regulation of PI3KC2β in a range of cancers including AML (Armstrong 
et al., 2002; Qian et al., 2002). By testing novel isoforms-specific inhibitors and siRNA to down-
regulate PI3KC2β we could show that also this PI3K isoform bears great potential as a 
therapeutic target. Different cancer cell lines were highly sensitive to PI3KC2β inhibitors and 
strongly reduced cell proliferation rate in a dose-dependent manner. Besides, inhibiting PI3KC2β 
sensitized AML and glioblastoma cells to chemotherapeutical agents. Taken together, we could 
describe an important role of PI3KC2β for cell survival and chemo-sensitization in various 
tumors. Additionally, studying highly motile breast cancer cells underlined the finding that 
PI3KC2β essentially contributes to cancer cell motility.  
 
Studying expression patterns of RTK signaling molecules in AML cells lead to the interesting 
finding of highly variable mTOR levels in the panel of cells analyzed. A significant contribution 
of mTOR to AML cell growth and cell cycle control had been described before and constitutive 
activation of signaling pathways involving mTOR was shown to commonly occur in AML 
patients (Kubota et al., 2004; Martelli et al., 2006; Recher et al., 2005). We therefore aimed at 
gaining a better understanding of this rather unexpected finding and compared cells expressing 
high levels of mTOR (mTORhigh cells) to cells expressing low levels only (mTORlow cells). By 
first comparing growth factor-induced pathway activation we could show that mTORlow were not 
able to phosphorylate the mTOR downstream targets S6 protein and 4E-BP to the same extent as 
mTORhigh cells. However, activation/phosphorylation of the upstream molecule Akt was 
comparable. In a next step we compared the response to the mTOR inhibitor rapamycin in the 
two groups of cells. Surprisingly, no striking differences in regard to cell proliferation, induction 
of apoptosis and cell cycle could be detected. This finding raised the question of additional 
targets of rapamycin in AML which was further underlined by the result that cells expression 
high levels of mTOR indeed seemed to be more dependent on this protein. siRNA-induced down-
regulation of mTOR namely significantly reduced cell proliferation in mTORhigh cells whereas 
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the growth rate of mTORlow was not affected. A siRNA screen was therefore aimed at uncovering 
human kinases which modulate the sensitivity to rapamycin in AML. First results screening 
mTORlow cells for proteins that had the strongest additive anti-proliferative effect brought the 
attention to certain RTKs such as the IGF-IR, FLT3 and the FGFR1, signal transducers such as 
SYK, ZAP70 and AKT1 to 3 as well as already well known oncogenes in leukemia like ABL1 
and ABL2. Further experiments are now focused on validation of these candidates, on the one 
hand by the use of shRNA and on the other hand by the use of available inhibitors to specifically 
target the proteins. So far we could show that the candidates indeed play an important role in 
growth of the cancer cells and that targeting these kinases in combination with rapamycin bears 
great potential in regard to combinatorial cancer therapy. In a next step, mTORhigh cells will be 
screened using the same kinase library. The comparison with the mTORlow cells will hopefully 
give further insight into the distinctness of the two groups and help elucidate the role of mTOR in 
AML cells.                  
 
In summary, the studies presented in this thesis underlined the significance of the RTK network 
in human cancer and yielded important findings which are relevant for the evaluation process of 
new molecular targets for AML.  
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